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Hypoxia Mediated Downregulation of miRNA Biogenesis Leads to Increased 
Tumor Progression 
Rajesha Rupaimoole, M.S. 
Advisory Professor: Anil K. Sood, M.D. 
In recent years, there has been a growing recognition of the importance of tumor 
associated microenvironment in the initiation and progression of tumors. However, a 
mechanistic understanding of the complicated biological interplay between the 
stromal framework and malignant regions of the tumor remains incompletely 
understood. In this study, we address mechanisms by which hypoxia in the tumor 
microenvironment leads to attenuation of miRNA biogenesis by downregulation of 
two key enzymes, Drosha and Dicer in cancer cells. Previous data from our 
laboratory had shown the clinical relevance of downregulated Dicer and Drosha in 
ovarian and other cancer types, but a clear mechanistic understanding is needed for 
future clinical intervention strategies to curb deleterious effect of miRNA biogenesis 
downregulation. Using several in vitro techniques, orthotopic in vivo models and 
clinical patient samples, we demonstrate novel deregulatory mechanisms involved in 
Dicer and Drosha downregulation under hypoxia. Data from deep sequencing of 
normoxia and hypoxia treated cells demonstrate clear effect of this downregulation 
on miRNA maturation. Collectively, we show substantial functional effects of this 
downregulation on cancer progression under in vivo conditions by use of siRNAs 
incorporated in liposomes mediated gene silencing. Our work will provide the 
missing links for this mechanistic understanding, with a goal of novel interventions to 
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rescue the Dicer and Drosha-miRNA biogenesis pathway. The findings described in 
this thesis have significant clinical implications with respect to understanding 
mechanisms of tumor growth and metastasis and the design of new therapeutic 
approaches in cancers. 
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Chapter 1: Introduction 
1.1: MicroRNAs - small noncoding RNA biogenesis and physiological 
functions 
MicroRNAs (miRNA) are evolutionarily conserved small RNA molecules that 
are involved in gene regulation by targeting mRNA to suppress gene expression [1-
3]. Currently over 1000 miRNAs have been identified and are involved in key cellular 
functions by regulating several important gene expression via controlling their 
translation [1]. These small RNA molecules are a key component of noncoding 
RNAs (ncRNA) and are involved in multiple cellular functions. Since the discovery of 
these short RNA molecules in C. elegans, their multi-faceted roles have been 
recognized to control cellular functions by repressing target genes [3-8].  
Mature miRNA biogenesis starts at RNA polymerase II processing of long primary 
transcripts (>100nts), termed precursor miRNAs [9]. This transcript gets further 
processed via Drosha along with its binding partners such as DGCR8, leading to pri-
miRNAs. Upon translocation of this pri-miRNA into the cytoplasm via exportin 5, it 
binds to Dicer and RNA-induced silencing complex (RISC), which includes 
argonaute proteins. After binding with the RISC complex, the guide strand helps to 
navigate the complex to the target mRNA and consequently results in 
downregulation of target genes [9] (Figure 1).  
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Figure 1: MicroRNA biogenesis, a multistep tightly controlled process. Canonical 
pathway of biogenesis starts at pri-miRNA produced by RNA polymerase II or III. 
Next, pri-miRNA is cleaved by Drosha-DGCR8 complex to yield pre-miRNAS, which 
gets exported into cytoplasm by XPO5-GTP nuclear export system. In cytoplasm, 
Dicer in conjugation with TRBP cleaves pre-miRNAs to mature duplex miRNAs. 
Later, Ago2 and RISC come together to select functional strand and silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation.  
(Figure is taken with permission from Winter, S.C., F.M. Buffa, P. Silva, C. Miller, 
H.R. Valentine, H. Turley, K.A. Shah, G.J. Cox, R.J. Corbridge, J.J. Homer, B. 
Musgrove, N. Slevin, P. Sloan, P. Price, C.M. West, and A.L. Harris, Relation of a 
hypoxia metagene derived from head and neck cancer to prognosis of multiple 
cancers. Cancer Res, 2007. 67(7): p. 3441-9.) 
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Drosha: DGCR8 microprocessor complex: RNA polymerase II or III processed 
miRNA genes into primary miRNA transcripts (pri-miRNA) in the nucleus [10]. 
Nuclear processor complex is composed of RNase III enzyme Drosha and binding 
partner DGCR8 cleaves the pri-miRNA by endonuclease type digestion. This 
cleavage happens via two double-stranded RNA-binding domains present in 
DGCR8. Human pri-miRNA contains a hairpin stem of 33 base-pairs, a terminal loop 
and two single-stranded flanking regions on both sides of hairpin towards 3’ and 5’ 
prime [1, 11]. Reports have suggested the importance of double-stranded stem and 
the unpaired flanking regions for cleavage by Drosha and DGCR8 complex. Drosha 
plays a central role in processing of pri-miRNA at 5’ and 3’ arms of hairpin. DGCR8 
is typically referred as a molecular ruler, which determines precise position at which 
Drosha cleaves the RNA [12]. The cleavage happens at 11 base pair away from 
single and double stranded RNA junction at the base of hairpin. Timing of this 
processing happens co-transcriptionally and precedes splicing events of coding or 
noncoding RNA that hosts the miRNA in some cases. Upon processing by 
Drosha/DGCR8 complex, pri-miRNAs are called precursor miRNAs and exported 
into cytoplasm by Exportin-5 (XPO5) in complex with Ran-GTP [13]. It is recognized 
that apart from the role as a transporter of pre-miRNA, XPO5 protects pre-miRNAs 
from nuclease digestion. Recognition of pre-miRNA by XPO5 is sequence 
independent and predominately by defined length of the double-stranded stem and 
the 3' overhangs.  
RNAi Induced Silencing Complex (RISC) – Dicer and Ago2 - Final players in 
miRNA function: RISC consists of RNase enzyme Dicer, the double-stranded RNA-
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binding domain proteins TRBP and PACT, and the core component Argonaute-2 
mediate the miRNA effects on mRNA targets [14-16]. Dicer is the core component of 
RISC and is involved in cleavage of pre-miRNA to result in mature miRNAs. TRBP 
and PACT are two proteins which facilitate Dicer mediated cleavage stem loop of 
pre-miRNA. Also, they are involved in the recruitment of Ago2 to the complex to 
facilitate the processing of mature miRNA [17]. In some cases with high 
complementarity along the hairpin loop, an additional Ago2 mediated cleavage of 3’ 
arm of hairpin produces Ago2-cleaved precursor miRNA [17-19]. Dicer is an RNase 
III type enzyme and cleaves the pre-miRNA at the hairpin loop to generate a 22-
nucleotide miRNA duplex. The DExD/H-box helicase domain present in Dicer protein 
inhibits this cleavage activity. Binding of TRBP to Dicer, helps to facilitate the release 
of this inhibitory domain via conformational changes. The PAZ (PIWI–AGO–
ZWILLE) domain present in Dicer protein is responsible for binding of Dicer to pre-
miRNA and, the region between PAZ and RNase III domains functions as a 
‘molecular ruler’ [20, 21].  Upon binding, Dicer cleaves pre-miRNA at 22 nt away 
from the 5’ end following 5’ counting rule [15]. Following unwinding and dissociation 
of Dicer-TRBP complex from miRNA duplex, RISC complex undergoes next step of 
miRNA function, i.e., duplex unwinding. Several helicases such as p68, p72, RNA 
helicase A (RHA), RCK/p54, TNRC6B, Gemin3/4 and human Mov10 or its D. 
melanogaster orthologue Armitage have been identified with this function [22].  
Some reports have also shown the role of Ago2 in unwinding duplex in the absence 
of helicases suggesting a dual role of Ago2. Following unwinding, the miRNA strand 
with thermodynamically less stable base pair at 5’ end is loaded into RISC.  
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Two mechanisms on how miRNAs downregulate gene expression has been 
identified: (1) mRNA cleavage and (2) translational repression. If mRNA-miRNA 
binding site has perfect complementarity, mRNA will be cleaved, otherwise miRNA 
represses translation [1, 23]. In the case of miRNA mediated mRNA cleavage, the 
site is in between the nucleotides pairing 10 to 11 of miRNA. It is also shown that 
miRNA gets recycled and can act on other mRNA following base complementarity 
rules. Regarding the translational repression, process is aided by RISC and 
miRNA/mRNA binding via cooperative action of multiple miRNA binding sites in the 
same mRNA.  
Physiological functions of miRNAs: Early discoveries of miRNA functions were 
carried out in classical model organisms such as C. elegans. Two key discovered 
miRNAs in C. elegans were lin-4 and let-7 [24, 25]. Both miRs are involved in 
developmental stages. Loss of lin4 results in significant defects in normal 
development and early embryonic cells have defective cell division processes [4, 
26]. Studies suggest Let7 is well conserved across species and has several 
developmental roles as well roles in disease physiologies, such as cancer [25]. Loss 
of Dicer functional studies show that Dicer is essential for normal embryonic 
development and Dicer-/- animals are embryonically lethal. In a Zebrafish model, 
loss of Dicer during development results in growth arrest and failure in development 
of organs [27]. Interestingly, restoration of one miRNA such as miR-430 could 
reverse this defective brain development in the Dicer-/- Zebrafish model [28]. In 
Dicer-/- mice, embryos die at embryonic day 8.5 with significant defects in stem cells 
[27].  
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One of the well-studied miRNAs, miR-181, has been shown to be important for 
development of B-lymphocytes [29]. This miRNA has been shown to regulate 
muscle differentiation by downregulation of HOXA11, which suggests strong roles of 
miRNAs in developmental physiology [30]. Another important miRNA involved in 
development of normal tissues is miR-1, which has been shown to play a role in 
muscle development [31]. Loss of miR-1 during development results in impaired 
muscle growth and differentiation defects. These effects of miR-1 were reported to 
be mediated via targeting of HDAC4 [32]. In summary, these miRNAs are great 
examples of the role of ncRNAs in normal physiology of cells and perturbation of 
their signaling could have profound significant effects on cells, resulting in initiation 
or progression of different types of diseases.    
1.2: MicroRNA dysregulation in cancer  
MiRNA biogenesis downregulation and clinical relevance: Downregulation of 
Drosha, Dicer, Ago2 in cancers: Over 6 years ago, downregulation of Drosha and 
Dicer, two key enzymes involved in miRNA biogenesis, was reported in many 
cancers including ovarian, lung and breast cancers [33, 34].  Such changes are 
functionally relevant since cells with deficient biogenesis have defects in miRNA 
processing [34]. Since then, several others have shown the importance of Drosha 
and Dicer in an array of cancer types [35-39]. Possible mechanisms for Drosha 
downregulation include transcriptional downregulation via c-myc [35] or ADARB1 
[36] proteins. For Dicer, direct binding of Tap63 transcription factor to Dicer promoter 
has been shown and downregulated Dicer due to loss of Tap63 in cancer has been 
observed [40]. Another study highlighted the mutant p53 dependency on p63 
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independent Dicer downregulation [41], suggesting layers of complexity in Dicer 
downregulation in cancer. Another layer of complexity in Dicer downregulation is via 
miRNAs targeting Dicer 3’ UTR. Two independent studies shown different miRNAs 
targeting Dicer, namely miR-103/107 [42] and let-7 [43]. Apart from Drosha and 
Dicer, other enzymes in the miRNA biogenesis pathway such as TARBP2, AGO2 
have also been reported to be downregulated in cancer. In sporadic and hereditary 
carcinomas, mutations leading to truncated form of TARBP2 protein can lead to 
impaired Dicer function [44]. Also, downregulation in TARBP2 protein expression in 
cancer stem cells was shown to be important for cancer pre-metastasis signaling 
[45]. EGFR dependent Ago2 phosphorylation results in hampering of Ago2 binding 
to Dicer, resulting in decreased miRNA biogenesis [46]. Even though the 
downregulation of these key enzymes involved in biogenesis is important for cancer 
progression, additional alterations in miRNA not related to biogenesis enzymes have 
been reported. DNA damage induces ATM kinase, which leads to increased 
processing of selective set of miRNAs [47]. Likewise, Hippo protein sequesters 
DDX17 and leads to decreased miRNA production [48]. Genetic defect in exportin-5 
results in hampering of precursor miRNAs exporting to cytoplasm for processing by 
Dicer [49] 
Key miRNAs deregulated in cancer and implications: One of the main miRNAs 
downregulated in cancer is the miR-200 family, which is involved in many diverse 
functions such as induction of EMT via downregulation e-cadherin, leading to 
increased ZEB proteins [50-52]. MiR-200 targets ETS1, and as result of loss of miR-
200 repression of ETS1 under hypoxia exposure, cancer cells induce angiogenic 
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responses [53]. We have demonstrated that miR-200 influences angiogenesis 
directly via downregulation of CXCL1 and IL8, two major cytokines in tumor 
microenvironment [54]. The Let-7 family members were shown to regulate cancer 
stem cells by targeting H-RAS and HMGA2 [55, 56]. Additional roles of Let-7 relate 
to regulation of several cell cycle regulators and proliferation [57]. Using in-silico and 
tumor samples’ analyses, master regulatory network of miRNAs involved in 
mesenchymal phenotype of cancer cells have been reported [58]. Some of the key 
miRNAs identified were miR-506, miR-200, and miR-25 [58]. MiR-10b is another 
important miRNA induced by Twsit1 protein, which targets homeobox D10, leading 
to increased RHOC protein and has been suggested to have a role in initiation of 
metastasis [59].   
1.3: Hypoxia as a tumor microenvironment factor: significantly influences 
tumor biology  
During cancer growth, tumors develop significant hypoxia and have been 
attributed to tumor promoting effects and resistance to therapy [60, 61]. Direct 
assessment of tumor hypoxia in clinical patient samples has shown worse patient 
outcome in the cohort of patients whose tumors are highly hypoxic [62].  Cancer 
cells evolve to grow under hypoxia conditions by modifying their key cellular 
metabolisms and gene alterations [60, 61]. During tumor growth and metastasis, 
cancer cells encounter significant amount of hypoxia due to improperly developed 
and tortuous blood vessels [62, 63]. 
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Role of hypoxia on miRNAs: In human endothelial cells, Dicer dependent miR-185 
was decreased under chronic hypoxia, and resulted in HIF2-α increase [64]. 
Interestingly, suppression of angiogenesis under complete loss of Dicer has been 
reported [65]. In tumor from Dicer-/- mice, significant increase in hypoxia due to 
reduced angiogenesis resulting from de-repression of HIF1 inhibiting factor called 
FIH1 was observed [65]. Anti-VEGF therapies have also been shown to induce 
hypoxia and cancers have aggressive tumor recurrence and increased invasiveness 
but the mechanisms are not clear.  An, important protein in the miRNA biogenesis 
pathway is Ago2, which is part of RNA induced silencing complex (RISC) complex. 
In cancer cells, under hypoxia exposure, EGFR phosphorylates Ago2 at Tyr 393 
results in decreased Ago2 function [46]. Ago2 phosphorylation results in decreased 
Dicer-Ago2 interaction, leading to decreased miRNA maturation and function [46]. 
However another study reported that Ago2 protein was increased due to 
posttranslational changes in hydroxylation under hypoxia exposure [66], suggesting 
multifaceted role of hypoxia in Ago2 regulation. In summary, the studies suggest a 
complexity in the miRNA biogenesis regulations and necessitates detailed 
investigations into tumor microenvrionmental influences on this important cellular 
machinery.  
Hypothesis and specific aims of the study: Hypoxia, a master tumor 
microenvironment factor influencing tumor progression via altering miRNA 
biogenesis 
Aim 1: To understand the mechanisms of hypoxia induced down regulation of Dicer 
and Drosha. 
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Hypothesis: Hypoxia induces down regulation of Dicer1 and Drosha, resulting in 
global deregulation of miRNA biogenesis. 
Rationale: Dicer1 and Drosha – two key components of miRNA processing 
machinery have been reported to be deregulated in cancer [34, 40]. Preliminary 
experiments based on mouse models show that Dicer1 and Drosha mRNA 
expression in tumors is heterogeneous and dynamic. These data suggest the 
greater influence of microenvironment factors in causing these effects. Our 
preliminary data show strong down regulation of Dicer1 and Drosha following 
exposure to hypoxia. Additional mechanistic experiments related to the deregulation 
of miRNA biogenesis will be carried out in this aim. 
Aim 2: To determine the biological significance of the miRNA processing machinery 
deregulation in tumor progression and metastasis. 
Hypothesis: Hypoxia induced deregulation of miRNA biogenesis results in driving 
EMT, resulting in aggressive tumor growth and progression.  
Rationale: Epithelial to mesenchymal transition has a significant contribution to the 
development of metastasis and aggressive cancer subtype [67, 68]. Our 
observations suggest that cells under hypoxia resemble fibroblast like structures, 
indicating EMT-like changes. In addition, molecular data show changes in the 
expression of gene signatures associated with EMT, suggesting strong induction of 
EMT upon exposure to hypoxia or treatment of cell lines with siRNA against Dicer or 
Drosha alone or in combination. However, the biological significance of miRNA 
deregulation under hypoxia is not known and will be pursued in this aim.   
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In this thesis study, we shed light on the understanding of tumor microenvironment 
factor, hypoxia influences on miRNA biogenesis and tumor growth. We show that 
hypoxia strongly inhibits miRNA biogenesis by downregulating two key enzymes in 
biogenesis, Dicer and Drosha, through two independent yet converging mechanisms 
in cancer cells. Drosha is downregulated by transcriptional repression mediated by 
ETS1/ELK1 through recruitment of methylation and histone de-acetylation related 
molecules onto promoter region. Dicer is downregulated by miR-630, which is 
upregulated in hypoxia. MiR-630 is transcriptionally upregulated under exposure to 
hypoxia by direct binding of STAT1 onto miR-630 promoter region. Further we show 
biological effects of miRNA downregulation using in vitro and in vivo models. 
Increased tumor invasiveness and growth was observed under downregulated 
miRNAs and we identified novel key miRNA-mRNA networks facilitating this 
increase in tumor progression.   
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Chapter 2: Material and Methods  
This chapter is based on Rupaimoole, R., S.Y. Wu, S. Pradeep, C. Ivan, C.V. Pecot, 
K.M. Gharpure, A.S. Nagaraja, G.N. Armaiz-Pena, M. McGuire, B. Zand, H.J. 
Dalton, J. Filant, J.B. Miller, C. Lu, N.C. Sadaoui, L.S. Mangala, M. Taylor, T. van 
den Beucken, E. Koch, C. Rodriguez-Aguayo, L. Huang, M. Bar-Eli, B.G. Wouters, 
M. Radovich, M. Ivan, G.A. Calin, W. Zhang, G. Lopez-Berestein, and A.K. Sood, 
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour 
progression. Nat Commun, 2014. 5: p. 5202.  
Copy right permission not required since Nature Communications journal policy 
states “Authors retains the copyright of the published materials”.  
Cell line maintenance and siRNA and miRNA transfections 
All cell lines were maintained in 5% CO2 at 37°C. Ovarian cancer (A2780, OVCAR3, 
SKOV3, OVCA432, HeyA8, IGROV, EG) and breast cancer (MDA-MB-231, MCF7, 
GILM2) cells were obtained from the American Type Culture Collection and were 
maintained in RPMI 1640 supplemented with 10-15% fetal bovine serum (FBS) and 
0.1% gentamicin sulfate (GeminiBioproducts, Calabasas, CA). All cell lines were 
routinely tested to confirm the absence of Mycoplasma, and all in vitro experiments 
were conducted with 60-80% confluent cultures.  
All siRNA transfections (Table 1) were performed using RNAiMAX (Invitrogen 
Carlsbad, CA) reagent using forward transfection protocol from the manufacturer. 
Media was changed 5 hours after transfections to minimize toxicity. For all hypoxia 
treatments, cells were incubated in an oxygen-controlled hypoxia chamber at 1% O2. 
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For ectopic expression of Drosha and Dicer, we obtained plasmids from Addgene 
(IDs 10828, 25851 respectively). Next, we cloned open reading frames into pLKO.1-
GFP or Puromycin lentiviral plasmids. We transduced HeyA8 cells with viral particles 
and then selection using GFP (Drosha) or puromycin (Dicer) was carried out to 
establish stable cell variants. 
In vivo models  
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY). 
These animals were cared for according to guidelines set forth by the American 
Association for Accreditation of Laboratory Animal Care and the US Public Health 
Service policy on Human Care and Use of Laboratory Animals. All mouse studies 
were approved and supervised by The University of Texas MD Anderson Cancer 
Center Institutional Animal Care and Use Committee. All animals used were 8-12 
weeks old at the time of injection.  
Orthotopic models of ovarian cancer were developed as described previously 
[69, 70]. For all animal experiments, cells were harvested using trypsin-EDTA, 
neutralized with FBS-containing media, washed, and resuspended to the appropriate 
cell number in Hanks’ balanced salt solution (HBSS; Gibco, Carlsbad, CA) prior to 
injection. For the A2780 model,  cells were injected either intraperitoneally (1 × 106 
cells in 200 µL of HBSS) or directly into the ovary (0.8 × 106 cells in a 1:1 mixture of 
BD Matrigel and HBSS with a total volume of 100 µL of HBSS). For the HeyA8 cells 
and variants expressing Drosha, Dicer, and Drosha+Dicer (0.8 × 106 cells in a 1:1 
mixture of BD Matrigel and HBSS with a total volume of 100 µL of HBSS) intra-
ovarian injections were performed. For the breast cancer model, MCF7 cells were 
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injected into the mammary fat pad (5 × 106 cells in a 1:1 mixture of BD Matrigel and 
HBSS). For the intra-ovary injections, mice were anesthetized with ketamine and 
xylazine. An incision just above the approximate site of the right ovary was made to 
visualize the ovary. A 1-mL tuberculin syringe with a 30-gauge needle was used to 
inject the cell suspension directly into the ovary. After injection, the incision was 
closed using surgical clips and the mouse was returned to a cage until fully 
recovered. For the orthotopic breast cancer model, the MCF7 cell mixture was 
injected into the second mammary fat pad from the top after the mouse was 
anesthetized with ketamine and xylazine. One week before the injection of breast 
cancer cells, a 60-day release pellet containing 0.72 mg of 17β-estradiol (Innovative 
Research of America, Toledo, OH) was implanted subcutaneously into each mouse.  
For all therapeutic experiments, a dose of 200 µg siRNA/kg, 200 µg 
miRNA/kg was used, as described previously [54, 70, 71]. For all models, unless 
indicated otherwise, twice weekly treatments were started 1 week after cell injection 
and continued for approximately 4 weeks. For miRNA or siRNA experiments, mice 
were randomly divided and treated with siRNA incorporated in neutral DOPC 
nanoliposomes (intraperitoneal administration). For the anti-VEGF therapy 
experiment, mice were allowed to develop tumors for 2-3 weeks and then 2 
treatments of bevacizumab (6.25 mg/kg) were administered. For the Drosha and 
Dicer rescue experiment, treatment with bevacizumab was started on day 7 after cell 
implantation and continued until the end of the experiment. In all experiments, once 
mice in any group became moribund they were killed and necropsied and tumors 
were harvested. Tumor weight and number and location of tumor nodules were 
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recorded. Tumor tissue was either fixed in formalin for paraffin embedding, frozen in 
optimal cutting temperature (OCT) media to prepare frozen slides, or snap-frozen for 
lysate preparation. 
Liposomal nanoparticle preparation  
MiRNA or siRNA for in vivo intratumor delivery was incorporated into DOPC, 
as previously described [71]. DOPC and miRNA or siRNA were mixed in the 
presence of excess tertiary butanol at a ratio of 1:10 (w/w) miRNA or siRNA:DOPC. 
Tween 20 was added to the mixture in a ratio of 1:19 Tween 20:miRNA/DOPC. The 
mixture was vortexed, frozen in an acetone/dry ice bath, and lyophilized. Before in 
vivo administration, this preparation was hydrated with phosphate-buffered saline 
(PBS) at room temperature at a concentration of 200 µg miRNA or siRNA/kg per 
injection. 
Tumor samples  
Tumor samples were obtained as per previously approved protocol [34]. We 
obtained 75 specimens of invasive epithelial ovarian cancer from The University of 
Texas MD Anderson Cancer Center Tumor Bank. For use as normal control, 15 
benign ovarian epithelial samples were also obtained. Frozen tumor samples 
(approximately 0.2 mg each) were used for total RNA isolation.  
TCGA data and bioinformatics analysis  
Bioinformatics analysis was performed in R (version 2.14.2; http://www.r-
project.org).   Statistical significance was set at p < 0.05. We downloaded and 
analyzed publicly available data from the Cancer Genome Atlas Project (TCGA; 
http://tcga-data.nci.nih.gov/) for patients with ovarian serous cystadenocarcinoma. 
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Level 3 Illumina RNASeq and miRNASeq were used to measure mRNA and miRNA 
expression. miRNASeq data were derived from the “isoform_quantification” files 
from the “reads per million miRNA mapped” values for mature forms of each 
microRNA. A list of 99 genes that comprised the hypoxia metagene was obtained 
from Winter et al [72]. Univariate Cox analysis was performed, and 10 genes with 
hazard ratio >1.1 (KCTD11, TNS4, TUBB2A, ANGPTL4, TEAD4, DPM2, PYGL, 
TPI1, C16orf74, and ADORA2B) were selected for further study. The median of the 
distribution was calculated for each patient.  
For survival analysis, the patients were grouped into percentiles according to 
the hypoxia metagene signature described above. We checked for an association 
between hypoxia signature and overall survival by choosing a cutoff to optimally split 
the samples into 2 groups, and the log-rank test was employed to determine the 
significance of the association. To examine the association between Drosha and 
Dicer levels and overall survival, the patients were grouped into sextiles according to 
DICER1 and DROSHA expression. We compared all groups and obtained the best 
separation (minimal log-rank test p value) for the groups linked to a positive 
association: DICER1 expression last sextile and DROSHA expression last sextile 
with DICER1 expression first sextile and DROSHA expression first sextile. We also 
compared miRNA levels between 2 additional groups: good responders and bad 
responders.   
MiRNA microarray and deep sequencing 
Total RNA was extracted from the A2780 cells under normoxic or hypoxic 
conditions using the mirVana RNA Isolation kit (Ambion). RNA purity was assessed 
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using Nanodrop spectrophotometric measurement (Thermo Scientific, Pittsburgh, 
PA) of the OD260/280 ratio with acceptable values falling between 1.9 and 2.1, as 
well as using Agilent Bioanalyser (Agilent Technologies, La Jolla, CA) with a RIN 
number of at least 8. Five hundred nanograms of total RNA was used for labeling 
and hybridization, according to the manufacturer’s protocols (Agilent Technologies). 
Expression levels of miRNAs in ovarian cancer cells upon exposure to hypoxia (1% 
O2) were profiled using miRNA microarray (Agilent v14). Bioinformatic analysis was 
performed in R (version 2.14.2). Statistical significance was set at p < 0.05. The raw 
intensity for each probe was the median feature pixel intensity with the median 
background subtracted, and setting an offset 1 ensured that no negative values 
would appear after log-transforming the data. Data were quantile-normalized and 
log2 transformed. A 2-sided t test was applied to determine significantly different 
miRNAs between samples. Heat maps were generated using the heat plot function 
of the library.  
Starting with 3 µg of total RNA for each sample, ribosomal RNA was depleted 
using Ribominus (Invitrogen/Life Technologies, Inc., Carlsbad, CA), following the 
manufacturer's recommendations. Sequencing libraries were then prepared and 
barcoded individually using the SOLiD™ Total RNA-Seq Kit for Whole 
Transcriptome Libraries (Life Technologies), following the manufacturer's 
recommendations. Prepared samples were then pooled and sequenced using the 
Life Technology 5500xl sequencer using 75 base forward read only. Data was 
extracted from XSQ files containing the read sequences, quality values were loaded 
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onto a compute cluster, and the reads were mapped in colorspace using the Life 
Technologies LifeScope 2.5.1 software, using default parameters.  
Reads were mapped to the human genome (hg19) downloaded from the 
UCSC Genome Bioinformatics Site (http://genome.ucsc.edu). The hg19 genome 
was slightly modified by deleting the Y chromosome to make a female genome. An 
hg19 exon reference file provided by Life Technologies was required by LifeScope to 
create the exon junction libraries needed to map reads that cross exon boundaries. 
This file was derived from the refGene database from UCSC. A human filter 
reference file was required (provided by Life Technologies) that contains the 
sequences of ribosomal and repetitive regions of the genome to filter reads that 
mapped to those regions.  
Mapped reads were exported in the standard BAM (Binary Alignment/Map) 
format. BAM files were imported into Partek Genomics Suite 6.6 (Partek 
Incorporated, St. Louis, MO) for gene expression analysis. Mapped reads contained 
in the BAM files were cross-referenced against the RefSeq database (downloaded 
from UCSC Genome Browser) and a small RNA database (UCSC Genome 
Browser) to generate RPKM (reads per kilobase of exon per million mapped reads) 
values for each gene. Low-expressing genes were excluded.  
Differential expression using the derived RPKM values was performed using 
analysis of variance. Genes with a false discovery rate <5% were considered 
significant. Significantly deregulated miRNAs from miRNA array and mRNA data 
from deep sequencing were uploaded onto ingenuity pathway network analysis 
(Ingenuity Systems®, www.ingenuity.com) and a network analysis with miRNA-
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mRNA target analysis was carried out to identify potential gene deregulation as a 
result of miRNA changes under hypoxic conditions.  
Target gene binding sites, luciferase reporter assays, and Dicer 3’ UTR site 
mutagenesis  
The putative miRNA binding sites on Dicer 3’ UTR were predicted 
bioinformatically using several algorithms for predicting miRNA targets. This was 
done using the following publically available sites: http://www.microrna.org for the 
miRanda algorithm, http://www.targetscan.org for the TargetScan algorithm, 
http://genie.weizmann.ac.il/pubs/mir07 for the PITA algorithm, 
http://cbcsrv.watson.ibm.com for the RNA22 algorithm, 
http://diana.cslab.ece.ntua.gr/microT for microT algorithm, and 
http://genome.ucsc.edu/cgi-bin/hgTables?command=start together with 
http://pictar.mdc-berlin.de/ for the PicTar algorithm. The predicted miRNAs were 
further shortlisted by cross-referencing with miRNA data from the miRNA array. 
GoClone pLightSwitch luciferase reporters for the 3’ UTR regions of Dicer were 
obtained from SwitchGear Genomics (Menlo Park, CA).  
A2780 and MCF7 cells were transfected with FuGENE HD TFX reagent in a 
96-well plate with scrambled control, miR-630 mimics (100nM; Ambion) along with 
the 3’ UTR reporter gene, and Cypridina TK control construct (pTK-Cluc). After 24 
hours of transfection, luciferase activity was obtained with the LightSwitch Dual 
Luciferase assay kits using a microplate luminometer, per manufacturer guidelines 
(Biotek, VT). Luciferase activity was normalized using the Cypridina TK control 
construct, and an empty luciferase reporter vector was used as a negative control. 
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The ratios obtained were further normalized according to the scrambled control. 
Mutants of the Dicer 3’ UTR were generated using the QuikChange Lightning Multi 
Site-direct Mutagenesis kit (Agilent Technologies), using the primers to mutate 5 
base pairs within the miR-630 binding site (Table 1). Mutagenesis was confirmed 
using Sanger DNA sequencing prior to luciferase assays. 
Immunoblotting  
Lysates from cultured cells were prepared using modified RIPA buffer (50mM 
Tris-HCl [pH 7.4], 150mM NaCl, 1% Triton, 0.5% deoxycholate) plus 25 µg/mL 
leupeptin, 10 µg/mL aprotinin, 2mM EDTA, and 1mM sodium orthovandate. The 
protein concentrations were determined using a BCA Protein Assay Reagent kit 
(Pierce Biotechnology, Rockford, IL). Lysates were loaded and separated on sodium 
dodecyl sulfate–polyacrylamide gels. Proteins were transferred to a nitrocellulose 
membrane by semidry electrophoresis (Bio-Rad Laboratories, Hercules, CA) 
overnight, blocked with 5% bovine serum albumin for 1 hour, and then incubated at 
4°C overnight with primary antibody (Dicer, Drosha [Littleton, Colorado], ETS1, 
ELK1, pELK1, STAT1, and pSTAT1 [Danvers, MA]. After washing with tris-buffered 
saline with Tween 20, the membranes were incubated with horseradish peroxidase 
(HRP)–conjugated horse anti-Mouse or Rabbit IgG (1:2000, GE Healthcare, UK) for 
2 hours. HRP was visualized using an enhanced chemiluminescence detection kit 
(Pierce Biotechnology). To confirm equal sample loading, the blots were probed with 
an antibody specific for β-actin (0.1 µg/mL; Sigma). 
Immunoprecipitation using antibodies against ETS1 or ELK1 was carried out 
using the Universal Magnetic Co-IP Kit (Active Motif, Carlsbad, CA)), according to 
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instructions provided by the company. Samples were processed for Western blotting 
as described above. Using the antibody against ARID4B (Novus Biologicals) and 
HDAC1 (Cell Signaling), pull-down samples were probed for interactions.  
 Quantitative real-time PCR  
For mRNA quantification, total RNA was isolated using the Qiagen RNeasy kit 
(Qiagen). For miRNA quantification, total RNA was isolated using the 
Trizol/isopropanol total RNA precipitation method. Using 1000 ng of RNA, cDNA was 
synthesized using a Verso cDNA kit (Thermo Scientific), as per manufacturer 
instructions. Analysis of mRNA levels was performed on a 7500 Fast Real-Time 
PCR System (Applied Biosystems) with SYBR Green-based real-time PCR for all 
genes except the one specified. Dicer and Drosha Taqman assays (Life 
Technologies) were performed. Specific primers used are described in extended 
data Table 1. Semi-quantitative real-time PCR was done with reverse-transcribed 
RNA and 100 ng/µL sense and antisense primers in a total volume of 20 µL. For 
miRNA quantification, total RNA was isolated using Trizol (Invitrogen) extraction. 
TaqMan miRNA assays (Life Technologies) were used for reverse transcription and 
real-time PCR, according to the manufacturer’s instructions. RNU6B was used as a 
housekeeping gene. RNA was isolated from nuclear and cytoplasmic fractionated 
cells using Paris kit (Life technologies, CA). Fractionation purity was confirmed by 
running the samples on agarose gel electrophoresis and visualization of precursor 
rRNA bands, 18s, and 28s rRNA bands. For pri-miRNA and mature miRNA 
quantifications, taqMan miRNA assays (Life Technologies, CA) were used and 
reverse transcription, real-time PCR were carried out, according to the 
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manufacturer’s instructions. Precursor miRNAs were quantified using miRscript 
precursor miRNA assays (Qiagen, CA). RNU6B (for mature miRNAs) or 18S (pri and 
precursor miRNAs) were used as a housekeeping gene. 
Immunostaining  
Staining was performed on OCT-embedded frozen tissue sections. Protein 
blocking of nonspecific epitopes was performed using 4% fish gelatin in tris-buffered 
saline with Tween 20 for 20 minutes. Slides were incubated with the primary 
antibody for Dicer, Drosha (Novus Biologicals), E-cadherin (BD Transduction 
Laboratories) or vimentin (Cell Signaling) overnight at 4°C. For immunofluorescence, 
secondary antibody staining was performed using either Alexa 594 or Alexa 488 
(Molecular Probes). Nuclear staining was performed using Hoechst 33342 
(Molecular Probes). Immunofluorescent images were captured using a Zeiss 
Axioplan 2 microscope and Hamamatsu ORCA-ER digital camera (Zeiss). Bright 
field light images of hematoxylin and eosin–stained lung tissue sections were 
obtained using a Nikon Microphot-FXA microscope and Leica DFC320 digital 
camera (Nikon, Japan; Leica, Germany). From each group, 10 images were taken at 
random and analyzed for micrometastasis, as well as scored for percentage of 
micrometastatic nodules.  
Migration and invasion assays  
Modified Boyden chambers (Coster, Boston, MA) coated with 0.1% gelatin 
(migration) or extracellular matrix components (invasion) were used. A2780 or MCF7 
cells (1 × 105) suspended in 100 µL of serum-free media were added into the upper 
chamber 24 hours after miRNA/siRNA transfections. Complete media for cells 
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containing 10% FBS (500 µL) was added to the bottom chamber as a chemo-
attractant. The chambers were incubated at 37°C in 5% CO2 for 6 hours (migration) 
or overnight (invasion). After incubation, the cells in the upper chamber were 
removed with cotton swabs. Cells were fixed and stained and counted using light 
microscopy. Cells from 5 random fields were counted. Experiments were done in 
duplicate and performed 3 times. 
Methylation specific PCR and Methylation specific restriction enzyme analysis 
For methylation-specific PCR, MethPrimer 
(http://www.urogene.org/methprimer/) software was used for the prediction of the 
CpG island of the Drosha promoter region and for design of methylation-specific 
primers (Table 1). Total DNA was isolated from normoxia- and hypoxia-treated cells 
using Phenol:Chloroform extraction and then treated with bisulphite using a 
methylation kit (EZ DNA Methylation-Gold; Zymo Research, CA). Using real-time 
PCR, as described above, quantification of methylation in hypoxia samples was 
performed by comparing them with normoxia samples. For methylation specific 
restriction enzyme analysis, primers were designed flanking the CpG island 
predicted by MethPrimer with at least two CpG islands on primers as suggested by 
qMethyl Light (Zymo Research, CA). DNA samples from hypoxia and normoxia 
exposed cancer cells were subjected to MSREs provided in kit. Following MSRE 
digestion of DNA, quantification of methylation was carried out using real-time PCR. 
Percentage methylation was calculated by comparing Ct values obtained from test 
(with MSRE) and reference (no MSRE) reactions as outlines in the kit manual.  
Northern blot analysis 
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RNA from cells treated with normoxia and hypoxia were subjected to Northern 
blot analysis using non-radioactive biotin-probe method[73]. Briefly, Total RNA from 
A2780 cells exposed to normoxia and hypoxia was loaded onto 15% Urea gel, 
electrophoresed and transferred to nylon membranes at 10–15 V (90 min) using 
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, CA). RNA was cross-linked to the 
membrane using UV cross linker. For miRNA and U6 probes, pre-synthesized LNA-
modified oligonucleotides were purchased from Exiqon (http://www.exiqon.com) with 
biotin conjugation. Hybridization and washing of the membranes were carried out 
using Northern max kit (Life Technologies, CA) according to the manufacturer 
recommended protocol.  Membranes were developed using Chemiluminescent 
Nucleic Acid Detection Module (Pierce Biotechnology, IL). 
Actinomycin D mRNA stability assay 
Drosha or Dicer mRNA stability under hypoxic and normoxic conditions was 
assessed using 5 µg/mL actinomycin D. Cells were grown in hypoxic or normoxic 
conditions for different time periods with or without actinomycin D. At specified time 
points, RNA was isolated and RNA levels of Drosha and Dicer were measured using 
real-time PCR, as described above. 18S was used to normalize between the 
hypoxia and normoxia samples. To assess RNA decay rates, Drosha and Dicer 
levels under hypoxic conditions after normalization with 18s were compared with 
Drosha and Dicer levels under normoxic conditions. 
Chromatin hybridization and immunoprecipitation assay 
Cells were cultured in hypoxic or normoxic conditions for 48 hours and 
chromatin immunoprecipitation assays were performed using the Chip-it express kit 
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(Active Motif), as described by the manufacturer. In brief, crosslinked cells were 
collected, lysed, sonicated, and subjected to immunoprecipitation with the ETS1 or 
ELK1 antibody or IgG isotype (mIgG) control. Immunocomplexes were collected with 
protein A/G agarose magnetic beads and eluted. Cross-links were reversed by 
incubating at 65°C with high salt concentration. PCR-based quantification of fold 
enrichment in ETS1 or ELK1 binding on the Drosha promoter region (primers used 
are listed in Table 1) was carried out. The 2500-3000 base upstream region of the 
ETS1 or ELK1 binding region was used as a control.  
 
Microdissection and RNA isolation 
In vivo tumor samples from a previous study [74] injected with Hypoxyprobe 
(Hypoxyprobe Inc., Burlington, MA) were used for the present study. Frozen sections 
(10 µm) were affixed onto polyethylene terephthalate slides (Leica), fixed in cold 
acetone (10 minutes), washed in PBS 3 times, stained for Hypoxyprobe using FITC-
conjugated antibody  for 1 hour on top of ice, washed, and air-dried; dissection 
immediately followed. Microdissection was performed using an MD LMD laser 
microdissecting microscope (Leica). RNA was isolated from some samples using the 
Cells to Ct Kit (Applied Biosystems), according to the manufacturer instructions. 
Real-time PCR was carried out to quantify gene expression.  
Transcription factor binding analysis, luciferase assays, and mutagenesis 
The promoter region of Drosha was analyzed for potential transcription factor 
binding using Matinspector (Genomatix Inc., Germany), followed by analysis for a 
potential gene suppression role using LitInspector (Genomatix). The Drosha 
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promoter luciferase reporter assay was performed in A2780 and MCF7 cells using 
the Dual Luciferase system (SwitchGear Genomics). Cells were transfected using 
FuGENE HD TFX reagent in a 96-well plate with empty promoter or Drosha 
promoter (Switchgear Genomics), along with the Cypridina TK control construct 
(pTK-Cluc). Cells were treated with hypoxia or normoxia for 48 hours and luciferase 
activity was measured using the kit as described above. Mutation in the ETS1 or 
ELK1 binding region in the Drosha promoter was created using the Quick change 
site-directed mutagenesis kit (Agilent Technologies) and verified by sequencing. 
Primers used for mutagenesis are listed in extended data Table 1.   
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Chapter 3: Hypoxia downregulates miRNA biogenesis 
This chapter is based on Rupaimoole, R., S.Y. Wu, S. Pradeep, C. Ivan, C.V. Pecot, 
K.M. Gharpure, A.S. Nagaraja, G.N. Armaiz-Pena, M. McGuire, B. Zand, H.J. 
Dalton, J. Filant, J.B. Miller, C. Lu, N.C. Sadaoui, L.S. Mangala, M. Taylor, T. van 
den Beucken, E. Koch, C. Rodriguez-Aguayo, L. Huang, M. Bar-Eli, B.G. Wouters, 
M. Radovich, M. Ivan, G.A. Calin, W. Zhang, G. Lopez-Berestein, and A.K. Sood, 
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour 
progression. Nat Commun, 2014. 5: p. 5202.  
Copy right permission not required since Nature Communications journal policy 
states “Authors retains the copyright of the published materials”.  
3.1 MiRNA biogenesis is dynamic in nature under in vivo conditions 
First, we determined whether tumors have stable heterogeneity with regard to 
Drosha and Dicer. We examined single-cell clones of A2780 ovarian cancer cells 
and found heterogeneous expression of Drosha and Dicer (Figure 2a). To 
understand the functional implications of this heterogeneity, we expanded and 
injected 2 single-cell clones of A2780 cells into the peritoneal cavity of mice (Clones 
2 and 4). Upon analysis of individual tumor samples, we observed that each sample 
had varying Drosha and Dicer expression levels compared with the expression of 
clones at the time of injection (Figure 2b).  
This prompted us to consider whether changes in expression levels of Drosha 
and Dicer could be dynamic and potentially affected by the tumor microenvironment. 
Considering the critical role of hypoxia in the tumor microenvironment[60-62], we 
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tested levels of hypoxia in the clones with low Drosha and Dicer, also A2780 tumor 
samples using a hypoxia marker, carbonic anhydrase 9 (CA9). In the cell clones, in 
vitro, we observed variable levels of CA9 with small magnitude of changes (Figure 
2c). In contrast, the tumor samples with low Drosha and Dicer levels displayed 
significantly increased expression of CA9, which was inversely correlated with 
Drosha (Figure 2d) and Dicer (Figure 2e) levels. This suggests possibility that 
hypoxia and miRNA biogenesis is linked together.  
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Figure 2: (a) mRNA expression levels of Drosha and Dicer in single-cell clones 
derived from A2780 cells. (b) mRNA expression levels of Drosha and Dicer in 
individual tumor samples from mice injected with A2780 clones (n = 4 per group). (c) 
Expression of CA9 (hypoxia marker) in single cells clones of A2780 cell line, 
compared to parental cells. (d-e) Spearman correlation between mRNA expression 
levels of Dicer and Drosha with carbonic anhydrase 9 (CA9) levels in individual 
tumor samples from mice injected with parental cells and single-cell clones. Data are 
presented as mean ± standard error of the mean of n ≥ 3 independent experimental 
groups.  *p < 0.05 (Student t test). 
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We next tested the effect of hypoxia on Drosha and Dicer levels using various 
cancer cell lines. In multiple cell lines exposed to hypoxia, we observed marked 
reductions in Drosha and Dicer mRNA and protein levels (Figure 3a-g). This 
observed downregulation was consistent across several time points (Figure 3e); the 
48-hour time point was selected for all subsequent experiments. Drosha and Dicer 
levels were significantly increased after cells were restored to normoxic conditions, 
demonstrating the dynamic nature of the regulation (Figure 3h). To test the 
possibility of HIF1α dependency in Drosha and Dicer downregulation, we examined 
Drosha and Dicer expression levels in mouse embryonic fibroblasts (MEFs) with 
wild-type HIF1α or HIF1α-knockout cultured under normoxic or hypoxic conditions. 
HIF1α-knockout MEFs showed complete abrogation in Drosha downregulation under 
hypoxia exposure and partial abrogation in Dicer downregulation (Figure 4a), 
suggesting that Drosha downregulation is highly dependent on HIF1α. Additionally, 
siHIF1α significantly rescued Drosha levels in hypoxia exposed A2780 cells and 
Dicer levels were partially rescued (Figure 4b). These data were further supported 
by stabilization of HIFα by CoCl2 in A2780 cells under normoxia.  Increased CA9 
was observed, followed by Drosha and Dicer downregulation in CoCl2-treated 
samples compared to control cells (Figure 4c).  
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Figure 3: (a) Drosha and Dicer mRNA expression levels under hypoxic 
conditions (1% oxygen, 48 hr) in A2780 cells. (b) Protein expression of Dicer, 
Drosha, hypoxia marker carbonic anhydrase 9 (CA9), HIF1α, HIF2α under hypoxic 
conditions in A2780, OVCAR3, and MCF7 cells. (c and d) Drosha and Dicer mRNA 
expression levels under hypoxic conditions for several ovarian and breast cancer 
cell lines at different time points. (e) Drosha and Dicer mRNA expression levels in 
several ovarian and breast cancer cell lines 48 hrs following hypoxia treatment. Data 
are normalized to normoxic conditions. (f) Protein levels of HIF1α, Dicer, and Drosha 
in OVCAR3 cells under hypoxic and normoxic conditions at 48 hr time point. Scale 
bar: 200 µm. (g) mRNA expression levels of Drosha and Dicer in A2780 cells after 
long durations of hypoxic conditions. Data are normalized to normoxic conditions. (h) 
mRNA expression levels of Drosha and Dicer in A2780 cells after 48 hr of hypoxia 
treatment and reversal to normoxic condition. Data are presented as mean ± 
standard error of the mean of n ≥ 3 independent experimental groups. *p < 0.05, **p 
< 0.01 (Student t test). 
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Figure 4: (a) Drosha and Dicer levels in mouse embryonic fibroblasts with wild-type 
HIF1α (+/+) or HIF1α-knockout (-/-) mouse embryonic fibroblasts under normoxic 
and hypoxic conditions for 48 hrs. (b) Western blot analysis of the protein expression 
of HIF1α, Drosha, and Dicer in cells treated with siControl or siHIF1α in normoxic or 
hypoxic conditions (48 hr). Vinculin used as loading control.   (c) Drosha, Dicer, and 
CA9 levels in CoCl2 treated A2780 cells under normoxia.  Data are presented as 
mean ± standard error of the mean of n ≥ 3 independent experimental groups. *p < 
0.05, **p < 0.01 (Student t test). 
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In RNA samples isolated from microdissected hypoxic regions of A2780 
tumor samples, we observed significantly increased expression of hypoxia markers, 
CA9 and GLUT1. In the same RNA samples, we observed 60% downregulation of 
Drosha and Dicer (Figure 5a, b). These data support our finding that hypoxia is an 
important regulator of Drosha and Dicer downregulation in cancer. As previous 
studies have shown that anti-VEGF therapies can increase hypoxia[75], we 
assessed Drosha and Dicer levels in mouse tumor samples following treatment with 
bevacizumab, an anti-VEGF agent. We observed increased CA9 expression and, 
consequently, significantly decreased Drosha and Dicer expression levels in tumors 
treated with bevacizumab compared with untreated controls (Figure 5c, d). To 
determine whether similar findings extend to clinical samples, we analyzed 
expression levels of Drosha, Dicer, and CA9 in human tumor samples (n=30). 
Results showed a significant inverse correlation between CA9 and Drosha and Dicer 
levels (Figure 5e).  
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Figure 5: (a) Laser microdissection of hypoxic areas of tumors, guided by 
Hypoxyprobe staining (green). Scale bar: 500 µm. (b) mRNA expression levels of 
hypoxia markers CA9 and GLUT1, as well as Dicer and Drosha expression levels, in 
normoxic and hypoxic regions of tumors isolated using microdissection. (c) mRNA 
expression levels of CA9, Drosha, and Dicer in A2780 mouse tumors treated with 
bevacizumab. (d) Protein expression levels of Dicer (red), Drosha (red), and CA9 
(green) in A2780 mouse tumor samples treated with bevacizumab compared with 
untreated controls. Nucleus indicated as Blue. Scale bar: 200 µm. (e) Pearson 
correlation between Dicer and Drosha mRNA expression levels and hypoxia marker 
CA9 levels (n=30). All images shown are representative and data are presented as 
mean ± standard error of the mean of n ≥ 3 experimental groups. *p < 0.05, **p < 
0.01, ***p < 0.001 (Student t test).  
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3.2: Effect of hypoxia on miRNA levels and clinical outcomes 
We next considered whether Drosha or Dicer downregulation leads to 
impaired miRNA biogenesis by carrying out miRNA microarray analysis of samples 
exposed to hypoxia or normoxia. Upon analysis of mature miRNA array data, we 
observed significant global miRNA downregulation following exposure to hypoxia 
(Figure 6a; Table 2). Analysis of precursor and mature miRNA levels from deep 
sequencing data revealed significant downregulation of mature miRNAs, compared 
to their precursors (Figure 6b; Table 2). Using qRT-PCR, we analyzed expression 
of seven significantly downregulated miRNAs from Figure 6a, in cells exposed to 
normoxia or hypoxia. There was a significant increase in pri-miRNA levels of six of 
seven miRNAs that were tested (Figure 6c). There was also significant 
downregulation of corresponding mature miRNA levels in response to hypoxia 
(Figure 6d), suggesting defective processing machinery under hypoxic conditions. 
Next, to understand the individual contribution of Drosha and Dicer downregulation 
in the miRNA processing downregulation, we carried out quantification of pri, 
precursor, and mature miRNAs in RNA from nuclear and cytoplasmic fractionated 
A2780 cells exposed to normoxia or hypoxia. RNA from nuclear fractionated 
samples had significantly upregulated pri-miRNA levels (Figure 6e), consistent with 
the total RNA data in Fig. 6c. Interestingly, we noted >40% reduction in precursor 
miRNA levels in hypoxia treated samples compared to normoxia (Figure 6f). 
Additionally, samples from hypoxia exposed cells had >60% reduction in mature 
miRNA levels compared to normoxia in the cytoplasmic fraction (Figure 6g). This 
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data was further validated by northern blot analysis of miR-16a and 27a in cancer 
cells exposed to normoxia and hypoxia (Figure 6h). 
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Figure 6: Hypoxia mediated downregulation in Drosha and Dicer results in 
decreased miRNA levels. (a), Heat map showing mature microRNA (miRNA) levels 
under hypoxic conditions, assessed using miRNA array data. (b), Heat map showing 
precursor miRNA levels under hypoxic conditions, along with the corresponding 
mature sense (mature) and antisense (mature*) levels. (c-d), Pri-miRNA and mature 
miRNA expression levels of significantly altered miRNAs under hypoxia exposure in 
A2780 cells. (e), Pri-miRNA levels in RNA extracted from nuclear fractionated A2780 
cells treated with normoxia and hypoxia.   (f-g), Precursor and mature miRNA levels 
in RNA extracted from cytoplasmic fraction of A2780 cells treated with normoxia and 
hypoxia. (h) Northern blot data showing expression of mature miRNAs in RNA 
samples from normoxia and hypoxia exposed A2780 cells. Probing for U6 used as 
loading control. Data are presented as mean ± standard error of the mean of n ≥ 3 
experimental groups. *p < 0.05,  **p < 0.01, ***p < 0.001 (Student t test).  
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Using the ovarian cancer data from the Cancer Genome Atlas project 
(TCGA), we investigated the effect of low Drosha and Dicer levels on mature miRNA 
levels and observed that most miRNAs (>80%) were affected by downregulation of 
Drosha and Dicer (Figure 7a). In the TCGA dataset, we observed significantly worse 
median overall survival with low Drosha and Dicer levels (Figure 7b). Using a 
hypoxia metagene signature [72], we examined the survival difference between 
patients with high vs. low hypoxia levels in their tumors, according to TCGA data. 
We observed significantly worse survival rates in patients whose tumors had high 
levels of hypoxia (Figure 7c).  
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Figure 7: (a) Heat map depicting the ratio of mature miRNAs to precursor miRNAs in 
cells with high or low Drosha and Dicer expression levels. (b) Kaplan-Meier overall 
survival curves for Cancer Genome Atlas project (TCGA) samples analyzed for low 
and high Drosha and Dicer expression levels (p < 0.001). (c) Analysis of TCGA 
samples for hypoxia levels and correlation with overall survival duration plotted using 
the Kaplan-Meier method (p < 0.001).  
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Chapter 4: Drosha downregulation under hypoxia exposure is mediated via 
ETS1/ELK1 transcription factors  
This chapter is based on Rupaimoole, R., S.Y. Wu, S. Pradeep, C. Ivan, C.V. Pecot, 
K.M. Gharpure, A.S. Nagaraja, G.N. Armaiz-Pena, M. McGuire, B. Zand, H.J. 
Dalton, J. Filant, J.B. Miller, C. Lu, N.C. Sadaoui, L.S. Mangala, M. Taylor, T. van 
den Beucken, E. Koch, C. Rodriguez-Aguayo, L. Huang, M. Bar-Eli, B.G. Wouters, 
M. Radovich, M. Ivan, G.A. Calin, W. Zhang, G. Lopez-Berestein, and A.K. Sood, 
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour 
progression. Nat Commun, 2014. 5: p. 5202.  
Copy right permission not required since Nature Communications journal policy 
states “Authors retains the copyright of the published materials”.  
Next, we investigated the mechanism by which hypoxia could regulate 
Drosha expression. There was no significant change in Drosha mRNA half-life under 
hypoxic conditions (Figure 8a), pointing to transcriptional regulation of Drosha. 
Luciferase activity for the Drosha and Dicer promoters showed a significant 
decrease in Drosha promoter luciferase activity after exposure to hypoxia in A2780 
cancer cells (Figure 8b). Additionally, there was no significant change in Drosha 
protein half-life with hypoxia, suggesting that the mechanism is likely to be 
transcriptional (Figure 8c).  To identify potential regulatory transcription factors, we 
carried out bioinformatics analyses using Matinspector and Matbase (Genomatix 
Inc.). In addition, we tested the role of previously reported transcription factors in the 
hypoxia mediated downregulation of Drosha [35, 76, 77]. There was no significant 
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change in Drosha following siRNA mediated silencing of Myc, NF-kB or SP-1 
transcription factors (Figure 8d). From the bioinformatics analysis, ETS1 and ELK1 
were found to have binding sites on opposite strands at very close proximity to the 
transcription initiation site (Figure 8e, Table 4), and a previous study demonstrated 
transcriptional downregulation of downstream genes when ETS1/ELK1 bind to 
regions with very close proximity to the transcription initiation site [78]. Consistent 
with these findings, we observed an increase in both mRNA and protein levels of 
ETS1 and ELK1 under hypoxic conditions (Figure 8f-h). Of note, we also observed 
an increase in pELK1 levels, suggesting that ELK1 is activated under hypoxic 
conditions (Figure 8f).  
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Figure 8: (a) Drosha mRNA half-life in A2780 cells exposed to normoxia and 
hypoxia in A2780 cells. (b), Relative luciferase reporter activity for the Drosha 
promoter region under hypoxic conditions. β-actin was used as a control. (c) Stability 
of Drosha protein in A2780 cells exposed to normoxia and hypoxia. Cycloheximide 
at 100ug/ml was used to block protein synthesis. (d) Drosha mRNA expression after 
siRNA mediated silencing of Myc, NF-kB, and SP-1 transcription factors under 
hypoxia exposure in A2780 cells. (e) Graphical representation of ETS1 and ELK1 
binding sites on the Drosha promoter region. (f) Protein expression of ETS1 and 
ELK1 under hypoxic conditions in various cell lines. (g) ETS, ELK1, and pELK1 
expression in A2780 cells across several time points. Quantitative data from 
Western blot are shown. (h) ETS1 and ELK1 mRNA expression levels under hypoxic 
conditions compared to normoxic conditions in MCF7 cells. Data are presented as 
mean ± standard error of the mean of n ≥ 3 independent experimental groups. 
***p<0.001, ****p<0.0001 (Student t test). 
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We observed rescue of Drosha promoter activity in cells with mutations at the 
ETS1 or ELK1 binding sites under hypoxic conditions (Figure 9a-b). Previous 
studies have demonstrated HIF1α-dependent increase in ETS1 [79] and ELK1 via 
MAPK signaling [80] under hypoxia exposure. Nevertheless, we tested the potential 
role of loss of miRNA repression under hypoxia exposure resulting in increased 
ETS1 and ELK1. In siDicer + siDrosha treated cells, we did not observe any 
significant changes in ETS1 or ELK1 expression (Figure 9c). Also, we tested for 
CA9 and VEGF changes in siDicer + siDrosha treated cells and observed no 
significant changes in their expression (Figure 9c), ruling out the possibility miRNA 
repression loss as a mechanism for CA9 or VEGF increase under hypoxia exposure. 
Next, we knocked down ETS1 and/or ELK1 to study the eff ect of these 2 proteins 
on Drosha levels (Figure 9d). Drosha expression was rescued after silencing ETS1, 
ELK1, or both, suggesting that ETS1 and ELK1 serve as transcriptional repressors 
for Drosha (Figure 9e). Chromatin immunoprecipitation (ChIP) assays with anti-
ETS1, anti-ELK1 were performed to confirm definitive binding of these elements in 
the promoter region. Compared with IgG or normoxic controls, significant enrichment 
in the binding of ETS1 and ELK1 to the promoter region of Drosha was observed in 
A2780 (Figure 9f) and MCF7 cells (Figure 9g) under hypoxic conditions. 
Additionally, we observed a significant reduction in polymerase II occupancy at the 
Drosha promoter region under hypoxia conditions (Figure 9f).  
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Figure 9: (a, b), Luciferase reporter activity for the wild-type (WT) Drosha 
promoter region and the ETS1 or ELK1 binding site–mutant Drosha promoter region 
under hypoxic conditions in (a), A2780 cells and (b), OVCAR3, MCF7 MRNA and 
protein expression levels of ETS1 (a) and ELK1 (b) after siRNA-mediated silencing 
of respective genes using 3 different sequences of siRNA in A2780 cells. (c), 
Expression of CA9, VEGF, ETS1, and ELK1 in A2780 cells treated with siRNA 
against Dicer and Drosha. (d) Protein expression levels of ETS1 and ELK1 after 
siRNA-mediated silencing of respective genes using 3 different sequences of siRNA 
in A2780 cells. (e) Drosha expression under hypoxic conditions, after ETS1 and 
ELK1 gene knockdown with 2 independent siRNA sequences in A2780 cells. (f) Anti-
ETS1, anti-ELK1, anti-POL II chromatin immunoprecipitation assay results showing 
fold enrichment of ETS1, ELK1, POL II binding to the Drosha promoter region in 
A2780 cells. Rabbit IgG was used as a control and real-time polymerase chain 
reaction (PCR) was used to quantitate the fold enrichment. Fold enrichment 1000 
base pair upstream of ETS1 and ELK1 binding region at the Drosha promoter under 
hypoxia conditions in A2780 cells, used as negative control. (g) Fold enrichment of 
ETS1 and ELK1 binding at the Drosha promoter region under hypoxic conditions 
(MCF7), assessed using chromatin immunoprecipitation assays. Data are presented 
as mean ± standard error of the mean of n ≥ 3 independent experimental groups. 
**p<0.01, ***p<0.001 (Student t test).  
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To elucidate potential mechanisms by which ETS family members 
transcriptionally repress Drosha levels, we performed ingenuity pathway network 
analysis. This analysis revealed that ETS1 could bind to the histone de-acetylation-
related molecule HDAC1 and that ELK1 could bind to the DNA methylation-related 
molecule ARID4B [81, 82] (Figure 10a). A concentrated CpG island was observed 
near the Drosha promoter region where ETS1 and ELK1 bind (Figure 10b). We 
performed methylation-specific polymerase chain reaction (MSP) reaction following 
treatment of DNA samples with bisulphite to study the impact of hypoxia on Drosha 
promoter methylation. Analysis of data revealed a significant increase in methylation 
at the ETS1 and ELK1 binding regions (Figure 10c, d) in DNA from cells exposed to 
hypoxia compared to normoxia cultured cells. Methylation specific restriction enzyme 
(MSRE) treatment and PCR analysis showed significant methylation at the CpG 
islands at the Drosha promoter region following in vitro hypoxia exposure or in 
bevacizumab treated in vivo tumor samples (Figure 10e). In addition, cells treated 
with siRNAs against ETS1 or ELK1 under hypoxia showed significant reversal of 
Drosha promoter methylation compared to cells treated with control siRNA (Figure 
10f).  
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Figure 10: (a and b) Ingenuity pathway network analysis of possible interacting 
molecules of ETS1 and ELK1 and graphical representation of the CpG island in the 
Drosha promoter region. Dotted box highlights the area covered by methylation-
specific primers. (c-d) Threshold cycle number of unmethylated (UM) and 
methylated (M) targeting primers under normoxic and hypoxic conditions in A2780 
and MCF7 cells. (e) Percentage methylation in Drosha promoter region CpG island 
measured using methylation specific restriction enzyme analysis. DNA from A2780 
cells exposed normoxia and hypoxia were used. (f) Threshold cycle number of 
unmethylated (UM) and methylated (M) targeting primers under normoxic and 
hypoxic conditions in A2780 cells treated with hypoxia and siETS1, siELK1 or 
combinations.  Data are presented as mean ± standard error of the mean of n ≥ 3 
independent experimental groups. *p<0.05, **p<0.01, ***p<0.001 compared to 
normoxia control, +p<0.05, ++p<0.01, compared to hypoxia control. (Student t test). 
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Treatment of cells with the methylation inhibitor, azacitidine, or the HDAC1 
inhibitor, valproic acid, under hypoxic conditions rescued Drosha levels, which was 
consistent with MSP or MSRE data (Figure 11a). In addition, in vivo tumor samples 
treated with azacitidine showed significant rescue of Drosha even under hypoxic 
conditions induced by anti-VEGF therapy (VEGF targeted antibody, B-20), with a 
corresponding increase in ETS1 and ELK1 levels (Figure 11b). Cells treated with 
the HIF1α antagonist topotecan [83] under hypoxic conditions showed rescue of 
Drosha by suppressing ETS1 across several time points (Figure 11c), confirming 
the role of HIF1α-mediated signaling in ETS1 expression. Importantly, 
immunoprecipitation of ETS1 and ELK1 from hypoxia-treated cells showed clear 
binding of ARID4B and HDAC1, respectively; this binding was abrogated by 
treatment of cells with siETS1 + siELK1 under hypoxia (Figure 11d).  
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Figure 11: (a) Drosha expression under hypoxic conditions in A2780 and MCF7 
cells exposed to azacitidine and valproic acid either individually or in combination. 
(b) Drosha, ETS1 and ELK1 expression levels in tumor samples treated with B-20, 
azacitidine, or both in a A2780 mouse model of ovarian cancer. (c) ETS1 and 
Drosha expression in A2780 cells treated with the HIF1α inhibitor topotecan under 
hypoxic conditions. (d) Anti-ARID4B and anti-HDAC1 chromatin immunoprecipitation 
assay results showing fold enrichment of ARID4B and HDAC1 binding to the Drosha 
promoter region in A2780 cells. Data are presented as mean ± standard error of the 
mean of n ≥ 3 independent experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001 
(Student t test). 
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In the A2780 mouse model of ovarian cancer, using DOPC nanoliposomes to 
deliver siRNAs against ETS1, ELK1, or both, we observed significant tumor 
reduction in the tumors treated with siETS1 and siELK1; the lowest tumor weight 
was observed in the combination treatment group (Figure 12a). Tumors from all 3 
treatment groups showed increased expression of Drosha compared with the control 
group, and a significant reduction in ETS1 and ELK1 was observed in the treatment 
groups (Figure 12b). In the MCF7 orthotopic breast cancer model, treatment with 
the combination of siETS1-DOPC and siELK1-DOPC resulted in similar biological 
effects, suggesting that ETS1- and ELK1-mediated Drosha deregulation is not 
limited to one particular cancer type (Figure 12c). To understand the clinical 
relevance to ETS1/ELK1 expression, we next examined the correlation of ETS1 and 
ELK1 with patient survival by analyzing mRNA expression of ETS1 and ELK1 in 
human ovarian tumor samples (n=74). Patients with high tumoral ETS1 or ELK1 
expression had significantly lower survival compared to those with low ETS1 or 
ELK1 expression (Figure 12d).  
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Figure 12: (a) Aggregate tumor mass from tumors in the mouse orthotopic ovarian 
cancer model treated with control, ETS1, ELK1, and combination siRNAs. (b) 
Average mRNA expression of Drosha, ETS1, and ELK1 in the same tumor samples. 
All images shown are representative and data are presented as mean ± standard 
error of the mean of n ≥ 3 experimental groups. (c) Effect of silencing ETS1 and 
ELK1 using siRNAs (Seq2) in the MCF7 mouse model of breast cancer. Tumor 
volume and aggregate tumor weight across 2 groups. Representative pictures 
showing tumor burden in two groups. (d) Overall disease specific survival of patients 
with human high grade serous ovarian cancer (n=74) based on tumoral ETS1 (a) 
and ELK1 (b) mRNA expression levels. Kaplan-Meier curves shown; differences in 
survival were calculated using log rank method. *p < 0.05, **p < 0.01, ***p < 0.001 
(Student t test).   
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Chapter 5: Hypoxia upregulated miR-630 mediates Dicer downregulation in 
hypoxia 
In contrast to Drosha, Dicer expression was not affected by actinomycin D-mediated 
inhibition of mRNA transcription under hypoxic conditions (Figure 13a). This 
prompted us to examine potential 3’ UTR-mediated Dicer mRNA degradation under 
hypoxic conditions. Dicer 3’ UTR luciferase reporter assays showed significant 
reduction in reporter activity after cells were exposed to hypoxia (Figure 13b). Also, 
Dicer promoter luciferase assay showed modest decrease in reporter activity under 
hypoxia exposure (Figure 13b). To determine the specific miRNAs that are 
potentially involved in the downregulation of Dicer, we performed an integrative 
analysis using publicly available miRNA target prediction software and a miRNA 
array that compares miRNA expression in normoxic conditions with hypoxic 
conditions (Table 4). Among the list of most significantly upregulated miRNAs, we 
found that miR-630 was validated to be one of the highly upregulated in hypoxia 
(Figure 13c) and it is also predicted to target Dicer. Transfection of miR-630 into 
cells resulted in significant downregulation of mRNA and protein expression levels of 
Dicer in A2780 cells (Figure 13d) and additional cell lines (Figure 13e). Treatment 
with anti-miR-630 under hypoxic conditions significantly rescued mRNA and protein 
expression of Dicer (Figure 13d). To address the definitive role of miR-630-
mediated downregulation of Dicer, we performed the Dicer 3’ UTR assay. There was 
a significant reduction in luciferase reporter activity in cells treated with miR-630 
compared with cells treated with control miRNA (Figure 13f). A mutation in the Dicer 
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3’ UTR region that corresponds to the miR-630 binding region resulted in abrogation 
of the effect of miR-630 on Dicer 3’ UTR luciferase reporter activity (Figure 13g). 
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Figure 13: (a) Dicer mRNA decay under hypoxic conditions (relative to normoxic 
conditions) in A2780 cells with and without treatment with actinomycin D. (b) 
Relative Dicer 3’ UTR and promoter luciferase reporter activity under hypoxic 
conditions. β-actin 3’ UTR or promoter was used as a control. (c) Expression of miR-
630 under hypoxic and normoxic conditions in A2780, OVCAR3, and MCF7 cells.  
(d) mRNA and protein expression of Dicer after transfecting cells with miR-630 
under normoxic conditions or with anti-miR-630 under hypoxic conditions in A2780 
cells (right panel) and additional cells (left panel). (e) Dicer 3’ UTR luciferase 
reporter activity with and without miR-630 in A2780 cell line (left panel). Dicer 3’ UTR 
wild type (WT) and mir-630 binding site mutant (mut) luciferase activity under 
hypoxia conditions in the A2780 and MCF7 cells (right panel). Data are presented as 
mean ± standard error of the mean of n ≥ 3 independent experimental groups.  *p < 
0.05, **p < 0.01, ***p < 0.001 (Student t test).   
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 Quantification of precursor miR-630 showed increased expression of pri-miR-
630 under hypoxic conditions, suggesting that miR-630 is transcriptionally 
upregulated (Figure 14a). Consistent with in vitro findings, in A2780 model tumor 
samples treated with bevacizumab, we found a substantial increase in miR-630 
expression both at mature and precursor levels (Figure 14b). Deep sequencing 
mRNA array data cross-referenced with miR-630 promoter analysis for potential 
transcription factor binding, suggested that STAT1 binding to the promoter region 
potentially leads to increased precursor levels of miR-630. Under hypoxic conditions, 
STAT1 and pSTAT1 levels were increased significantly at the mRNA and protein 
levels (Figure 14c). Use of siRNA-mediated gene silencing led to significant STAT1 
gene knockdown (Figure 14d). Expression of Dicer was significantly rescued under 
hypoxic conditions by treating cells with siSTAT1, and a corresponding reduction in 
miR-630 expression levels (Figure 14e) was also observed.  
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Figure 14: (a) Expression of Pri-miRNA-630 levels in A2780, OVCAR3, and MCF7 
cells exposed to hypoxia. (b) Mature and pri-miRNA-630 levels in A2780 mouse 
tumor samples treated with bevacizumab, a VEGF antibody. (c) Western blot data 
showing protein expression of STAT1 (total STAT1 and phospoSTAT1) under 
hypoxic conditions in A2780 and MCF7 cells. (d) Efficiency of siRNAs targeting the 
STAT1 gene, as well as STAT1 mRNA expression under hypoxic conditions.  (e) 
mRNA levels of miR-630 and Dicer in the hypoxia-treated cells with or without 
STAT1 gene knockdown using siRNAs. Data are presented as mean ± standard 
error of the mean of n ≥ 3 independent experimental groups. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p<0.0001 (Student t test). 
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To understand the biological implications of miR-630 mediated Dicer 
downregulation under hypoxic conditions, we delivered miR-630 to A2780 tumors in 
vivo. There was significantly increased tumor burden and metastasis following 
treatment with miR-630-DOPC (Figure 15a-d). We observed metastases in several 
organs such as omentum, liver in miR-630 treated group while no metastasis was 
observed in control miRNA treated group (Figure 15d). Importantly, decreased Dicer 
expression was observed in tumors from mice treated with miR-630 (Figure 15e). 
We also examined 30 human epithelial ovarian cancer samples, which showed an 
inverse correlation between Dicer and miR-630 expression (Figure 15f). In addition, 
we observed a significant positive correlation between miR-630 expression and CA9 
levels in these clinical samples (Figure 15f).  
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Figure 15: (a-b) Aggregate tumor mass and photon counts from tumors in the 
mouse orthotopic ovarian cancer model treated with control microRNA and miR-630 
(n = 10 per group). (c) Representative pictures showing tumor burden using 
luminescence from the tumors (top) and gross tumor mass in the lung, showing a 
rare metastasis nodule in the miR-630 group (bottom). (d) Pattern of metastatic 
spread in mice treated with control microRNA and miR-630. (e) mRNA and protein 
expression levels of Dicer in A2780 mouse tumor samples treated with control 
microRNA or miR-630. (f) Pearson correlation graphs showing Dicer vs miR-630, 
miR-630 vs CA9 expression level correlation in clinical tumor samples. All images 
shown are representative and data are presented as mean ± standard error of the 
mean of n ≥ 3 experimental groups. **p < 0.01 (Student t test). 
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Chapter 6: Hypoxia downregulation of Drosha and Dicer leads to increased 
tumor progression  
This chapter is based on Rupaimoole, R., S.Y. Wu, S. Pradeep, C. Ivan, C.V. Pecot, 
K.M. Gharpure, A.S. Nagaraja, G.N. Armaiz-Pena, M. McGuire, B. Zand, H.J. 
Dalton, J. Filant, J.B. Miller, C. Lu, N.C. Sadaoui, L.S. Mangala, M. Taylor, T. van 
den Beucken, E. Koch, C. Rodriguez-Aguayo, L. Huang, M. Bar-Eli, B.G. Wouters, 
M. Radovich, M. Ivan, G.A. Calin, W. Zhang, G. Lopez-Berestein, and A.K. Sood, 
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour 
progression. Nat Commun, 2014. 5: p. 5202.  
Copy right permission not required since Nature Communications journal policy 
states “Authors retains the copyright of the published materials”.  
To identify potential tumor promoting pathways affected by hypoxia, we 
analyzed mRNA expression data from deep sequencing coupled with miRNA 
expression data from miRNA array analysis of A2780 cells exposed to hypoxia and 
normoxia. Ingenuity pathway network analysis of mRNA and miRNA data from deep 
sequencing identified key novel miRNA-mRNA interactions that could potentially 
lead to enhanced tumor progression under hypoxic conditions (Table 5). MiR-200, a 
well-studied miRNA to play role in cancer growth and metastasis, was one among 
the hypoxia activated networks identified. Pathway enrichment analyses revealed 
that cell adhesion, migration, and growth networks were the most significantly 
upregulated pathways under hypoxic conditions (Figure 16a). Cells under hypoxic 
conditions had consistent upregulation of RHOB1, TAGLN, SRTAD1, TXNIP, JAG1, 
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CTGF, and JUN, while corresponding miRNAs let7a, miR-135a, miR-146a, and miR-
30c were significantly downregulated under hypoxic conditions (Figure 6, 16b). 
Dicer, and Drosha silencing under normoxia resulted in similar downregulation of the 
aforementioned miRNAs and corresponding upregulation of genes (Figure 6, 16b). 
Ectopic expression of Dicer and Drosha under hypoxia exposure resulted in rescue 
of the miRNAs and corresponding downregulation of mRNA targets (Figure 6, 16b). 
In addition, we tested the known miR-185 and HIF2α axis [64] in the A2780 cancer 
cells following exposure to hypoxia. MiR-185 was significantly downregulated along 
with corresponding upregulation of HIF2α (Figure 16c). Additionally, rescue of miR-
185 by Drosha and Dicer ectopic expression or delivery of miR-185 mimics under 
hypoxia exposure resulted in significant downregulation of HIF2α (Figure 16c). 
These data further support the role of hypoxia-mediated Dicer and Drosha 
deregulation in hypoxia signaling and tumor progression. Consistent with the altered 
pathways described above, enhanced epithelial-to-mesenchymal transition (EMT) 
features were observed in cells under hypoxic conditions in A2780 and several 
additional cell lines (Figure 16d, e).  
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Figure 16: (a) Top 5 molecular functions that are significantly altered as result of 
mRNAs (left) or miRNAs (right) deregulated under hypoxic condition. Data are from 
RNA deep sequencing and miRNA arrays from cells exposed to hypoxia and 
normoxia. Data were analyzed using ingenuity pathway network analysis. (b) 
Expression of significantly altered pro-miRNAs (a) and metastatic genes (b) in Dicer 
and Drosha knocked down A2780 cells under normoxia (data shown normalized to 
siControl) or ectopic expression of Dicer and Drosha under hypoxia (data shown 
normalized to control), N - normoxia and H - hypoxia. (c)  Expression of miR-185 
and HIF2α in A2780 cells exposed normoxia, hypoxia, and cells ectopically 
expressing Dicer and Drosha exposed hypoxia. (d-e) E-cadherin, vimentin 
expression levels under hypoxic exposure in A2780 cells (d) and additional cell lines 
(e). Blue - Nucleus, Scale bar: 200 µm. Data are presented as mean ± standard 
error of the mean of n ≥ 3 independent experimental groups. *p<0.05, **p<0.01, 
***p<0.001 (Student t test). 
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Table 5: Ingenuity miRNA-mRNA target analysis of upregulated mRNAs and downregulated 
miRNA  data from cells exposed to hypoxia for 48hrs 
miRNA Symbol Fold Change Target Symbol Fold Change 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ADAMTS1 1.282 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 APBB3 1.132 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 BLOC1S6 1.049 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 BTG2 1.410 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 C8orf58 1.036 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 CACNA1I 1.662 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 CDKN1A 2.696 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 DUSP1 1.039 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ERGIC1 1.176 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ERO1L 1.770 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 FAM43A 1.004 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 FAM84B 2.062 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 FGF11 1.348 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 GLRX 1.667 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 HAND1 1.299 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 HK2 1.760 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 HMOX1 1.615 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 KIAA1244 1.781 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 LAMP2 1.465 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 LCOR 1.124 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 MEF2D 1.467 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 MGAT3 1.248 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 NIPA1 1.111 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 NSD1 1.049 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 OPA3 1.089 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 PANX2 2.065 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 PIK3IP1 1.162 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 PLD3 1.173 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 PTP4A2 1.349 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 PTPRU 1.168 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RBM38 1.055 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RGS16 1.133 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RHOB 2.088 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RIMKLA 1.216 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RIOK3 1.137 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RNF165 1.396 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 RRAGD 2.537 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 SBK1 1.336 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 SEC14L5 1.227 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 SLC25A4 1.245 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 SULF2 1.185 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 SYT11 1.129 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 TAGLN 3.009 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 TEAD3 1.352 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 TMEM194A 1.019 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ZBTB5 1.316 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ZMAT3 1.827 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ZNF275 1.185 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ZNF652 1.135 
let-7a-5p (and other miRNAs w/seed GAGGUAG) -2.743 ZSWIM4 1.474 
miR-100-5p (and other miRNAs w/seed ACCCGUA) -2.267 FGFR3 1.093 
miR-100-5p (and other miRNAs w/seed ACCCGUA) -2.267 RRAGD 2.537 
miR-100-5p (and other miRNAs w/seed ACCCGUA) -2.267 ZNF483 1.449 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 ABCA1 1.079 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 ANKRD44 1.184 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 ANXA2 1.210 
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miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 BLOC1S6 1.049 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 C3orf58 1.041 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CCNG2 1.522 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CEBPA 1.103 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CGGBP1 1.049 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CREB1 1.133 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CSRNP2 1.827 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 CSRP2 1.708 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 DDIT4 1.032 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 DUSP1 1.039 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 DUSP5 1.262 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 FAM73A 1.318 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 FAM84B 2.062 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 FGFR3 1.093 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 FOS 1.838 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 HNRNPU 1.486 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 JUNB 1.051 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 KIAA1244 1.781 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 LCOR 1.124 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 MCL1 1.009 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 MEF2D 1.467 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 N4BP2 1.143 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 NDRG4 2.087 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 NSD1 1.049 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 PCDH7 1.417 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 PHLDA1 2.392 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 POLH 1.072 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 PPFIA4 1.955 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 SCN2A 1.391 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 SYT11 1.129 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 TEAD3 1.352 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 TP53INP1 2.279 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 TRIM9 2.268 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 UNKL 1.007 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 WSB1 1.697 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 ZBTB5 1.316 
miR-101-3p (and other miRNAs w/seed ACAGUAC) -1.187 ZMAT3 1.827 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 CREB1 1.133 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 E2F7 1.181 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 ELAVL3 2.393 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 EPHA2 1.001 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 LCOR 1.124 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 LRRFIP1 1.351 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 POLH 1.072 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 PTP4A2 1.349 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 RAP2A 1.052 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 RNF165 1.396 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 SCARB2 1.076 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 SSPN 1.003 
miR-10a-5p (and other miRNAs w/seed ACCCUGU) -1.490 WDR26 1.935 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 ADAMTS1 1.282 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 ANKRD44 1.184 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 CACNB3 1.353 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 CREB1 1.133 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 CYTH2 1.322 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 DNAJB2 1.439 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 DPYSL4 2.528 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 DUSP3 1.718 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 EXO5 1.247 
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miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 FAM73A 1.318 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 GLTP 1.437 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 GPR160 1.030 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 HK2 1.760 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 ID2 1.682 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 KIAA1244 1.781 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 LCOR 1.124 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 MCL1 1.009 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 MEF2D 1.467 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 MXD4 1.829 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 NIPA1 1.111 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 PERP 1.026 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 PPME1 1.186 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 PSTPIP2 1.485 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 RAPGEFL1 1.031 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 RBM38 1.055 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 RIMKLA 1.216 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 RYBP 1.208 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 SCARB2 1.076 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 SCARF2 1.021 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 STAT3 2.118 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 STX6 1.220 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 SUN1 1.178 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 TMEM194A 1.019 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 TP53INP1 2.279 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 WDR1 1.065 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 ZNF652 1.135 
miR-125b-5p (and other miRNAs w/seed CCCUGAG) -2.271 ZSWIM4 1.474 
miR-1263 (miRNAs w/seed UGGUACC) -1.215 CSRNP1 2.331 
miR-1263 (miRNAs w/seed UGGUACC) -1.215 GBE1 1.498 
miR-1276 (miRNAs w/seed AAAGAGC) -1.278 LAMP2 1.465 
miR-1287-5p (miRNAs w/seed GCUGGAU) -1.187 TEAD3 1.352 
miR-1288-3p (miRNAs w/seed GGACUGC) -1.101 EXO5 1.247 
miR-1288-3p (miRNAs w/seed GGACUGC) -1.101 LAMP2 1.465 
miR-1288-3p (miRNAs w/seed GGACUGC) -1.101 SMAD7 1.135 
miR-1288-3p (miRNAs w/seed GGACUGC) -1.101 ZYX 1.635 
miR-1305 (miRNAs w/seed UUUCAAC) -1.167 GALNT3 1.021 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 CCNG2 1.522 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 CNTNAP1 1.190 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 DUSP5 1.262 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 HNRNPU 1.486 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 JADE1 1.702 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 KDM5B 1.270 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 KIAA1244 1.781 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 KLHL28 1.155 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 LRRFIP1 1.351 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 MCL1 1.009 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 MTURN 1.126 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 NCKIPSD 1.502 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 NDRG4 2.087 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 PLEKHA2 2.391 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 PTPRF 1.930 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 RAP2A 1.052 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 RIMKLA 1.216 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 RRBP1 1.139 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 RYBP 1.208 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 SCN2A 1.391 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 SERTAD2 1.719 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 STX6 1.220 
81 
 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 TXNIP 1.918 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 VGLL4 1.395 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 VLDLR 1.193 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 WDR45B 1.383 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 ZNF275 1.185 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 ZNF652 1.135 
miR-135a-5p (and other miRNAs w/seed AUGGCUU) -1.464 ZSWIM4 1.474 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 ABCA1 1.079 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 CREB1 1.133 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 CYTH2 1.322 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 DCLRE1C 1.132 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 HEY1 1.133 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 IGSF3 1.003 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 LAMP2 1.465 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 LCOR 1.124 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 MEF2D 1.467 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 MYH9 1.022 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 PLOD1 1.088 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 PTP4A2 1.349 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 RIOK3 1.137 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 SCARB2 1.076 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 SLC2A1 1.583 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 SMAD3 1.013 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 STC2 1.551 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 SULF2 1.185 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 TP53INP1 2.279 
miR-140-5p (and other miRNAs w/seed AGUGGUU) -1.176 ZNF652 1.135 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 ANKRD44 1.184 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 ARL4A 1.065 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 ATRN 1.085 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 BHLHE40 1.610 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 CACNA1I 1.662 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 CGGBP1 1.049 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 DUSP3 1.718 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 EGLN1 1.478 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 EPHA2 1.001 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 EXOC7 1.178 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 FAM84B 2.062 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 GLRX 1.667 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 GPRC5C 2.499 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 IRF2BPL 1.501 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 KIAA0408 1.050 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 KIAA1715 1.239 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 MBTD1 1.374 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 NRIP3 1.307 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 PAQR7 1.135 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 PDCD4 1.269 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 PDXP 1.048 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 PRKAR1A 1.012 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 RYBP 1.208 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 SCARB2 1.076 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 SHROOM4 1.366 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 SIDT2 1.420 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 TP53INP1 2.279 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 YPEL5 1.866 
miR-141-3p (and other miRNAs w/seed AACACUG) -1.658 ZMAT3 1.827 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 BTG2 1.410 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 CNTFR 1.302 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 FAM43A 1.004 
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miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 LCOR 1.124 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 NRIP3 1.307 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 NSD1 1.049 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 RRM2B 1.367 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 SLC2A3 1.781 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 STAT1 1.423 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 TMEM194A 1.019 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 TPM1 1.385 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 VASN 1.865 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 VWCE 1.179 
miR-146a-5p (and other miRNAs w/seed GAGAACU) -1.397 ZNF652 1.135 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 ADAMTS1 1.282 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 AHNAK2 1.604 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 AK4 1.350 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 BTG2 1.410 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 C8orf58 1.036 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 CNTNAP1 1.190 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 CSRNP1 2.331 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 CSRNP2 1.827 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 E2F7 1.181 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 EGLN1 1.478 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 FAM73A 1.318 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 GLRX 1.667 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 GLS2 1.156 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 HMOX1 1.615 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 HPCAL4 1.720 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 IRF2BPL 1.501 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 JUN 2.508 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 LAMP2 1.465 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 LCOR 1.124 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 MCL1 1.009 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 NCKIPSD 1.502 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 NFE2L1 1.418 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 NISCH 1.496 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PAM 1.554 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PDCD4 1.269 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PFKFB4 2.462 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PHLDA3 1.593 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PLEKHA1 1.476 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 PPM1D 1.536 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 RAB11FIP5 1.155 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 RAPGEFL1 1.031 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 RNF24 1.347 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SESN1 2.178 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SHROOM4 1.366 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SIDT2 1.420 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SLC16A3 1.081 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SLC22A17 1.103 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SLC2A14 1.169 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SLC2A3 1.781 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SMAD3 1.013 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SMAD7 1.135 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SQSTM1 1.301 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 SYDE1 1.791 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 TMEM41B 1.076 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 TMEM74B 1.796 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 TXNIP 1.918 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 WSB1 1.697 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 ZMAT3 1.827 
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miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 ZNF275 1.185 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 ZNF652 1.135 
miR-16-5p (and other miRNAs w/seed AGCAGCA) -1.667 ZYX 1.635 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ABCA1 1.079 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 AHNAK 2.181 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 AK4 1.350 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ARL4A 1.065 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 BNIP3L 2.633 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 C2orf69 1.023 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 CALD1 2.292 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 CCNG2 1.522 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 CDKN1A 2.696 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 CITED4 1.154 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 CREB1 1.133 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 EGLN1 1.478 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 FAM13A 1.877 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 GPR137B 1.176 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 IL17RD 1.007 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 IRF1 1.183 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 KIAA1191 1.452 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 KLHL28 1.155 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 LCOR 1.124 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 MCL1 1.009 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 MEF2D 1.467 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 MTURN 1.126 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 NRIP3 1.307 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 PAM 1.554 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 PANX2 2.065 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 PFKFB3 2.352 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 PFKP 1.390 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 PTP4A2 1.349 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RAB11FIP1 1.382 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RAB11FIP5 1.155 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RAPGEFL1 1.031 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RASD1 1.248 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RIMKLA 1.216 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RRAGD 2.537 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RUNDC1 1.386 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 RYBP 1.208 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SCN2A 1.391 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SERTAD2 1.719 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SLC25A36 1.011 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SLC41A1 1.067 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SMAD7 1.135 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SQSTM1 1.301 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 STAT3 2.118 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 STRIP2 1.321 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 STX6 1.220 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 SYAP1 1.464 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 TP53INP1 2.279 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 TRIM8 1.201 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 TXNIP 1.918 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ULK1 1.292 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 UNKL 1.007 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 VLDLR 1.193 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ZMAT3 1.827 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ZNF652 1.135 
miR-17-5p (and other miRNAs w/seed AAAGUGC) -1.677 ZNFX1 1.146 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 ADAMTS1 1.282 
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miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 ADM 3.046 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 AHNAK 2.181 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 AKIRIN1 1.234 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 ANKRD44 1.184 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 BHLHE40 1.610 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 BLOC1S6 1.049 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 C12orf68 1.158 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 C2orf69 1.023 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 CCDC92 1.133 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 CEBPA 1.103 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 CREB1 1.133 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 CYR61 1.894 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 DDIT4 1.032 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 DUSP5 1.262 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 E2F7 1.181 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 EGR1 1.452 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 FGFR3 1.093 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 FOS 1.838 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 KIAA1244 1.781 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 KIAA1715 1.239 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 KLHL3 1.151 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 LCOR 1.124 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 LOX 2.206 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 LRRFIP1 1.351 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 MCL1 1.009 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 MTURN 1.126 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 PAM 1.554 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 PDCD4 1.269 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 PHLDA1 2.392 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 PLAU 1.024 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 PTGR2 1.691 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 RIMKLA 1.216 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SEMA3B 1.395 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SERTAD2 1.719 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SLC25A36 1.011 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SLC25A4 1.245 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SLC2A3 1.781 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SLC35E1 1.692 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 SMAD7 1.135 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 STC2 1.551 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 TUB 1.001 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 UNKL 1.007 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 VGLL4 1.395 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 WSB1 1.697 
miR-181a-5p (and other miRNAs w/seed ACAUUCA) -1.236 ZNF652 1.135 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 ABCA1 1.079 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 AHNAK 2.181 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 APAF1 1.406 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 CGGBP1 1.049 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 CHSY1 1.071 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 CITED2 1.161 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 CNTFR 1.302 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 CREB1 1.133 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 DDIT4 1.032 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 DUSP1 1.039 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 EGLN1 1.478 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 GATA2 1.639 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 GLRX 1.667 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 HNRNPU 1.486 
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miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 IGSF3 1.003 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 JAG2 1.112 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 JUN 2.508 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 KLHL3 1.151 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 LCOR 1.124 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 LIN7B 1.032 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 LOX 2.206 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 MAPK7 1.067 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 MEF2D 1.467 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 MGAT3 1.248 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 MXD4 1.829 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 N4BP2 1.143 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 NOTCH1 1.667 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 NRIP3 1.307 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 PAM 1.554 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 PRKAR1A 1.012 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 SESN1 2.178 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 SNAPC1 1.052 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 SYDE1 1.791 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 TP53INP1 2.279 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 VLDLR 1.193 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 WDR45B 1.383 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 ZBTB5 1.316 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 ZMAT3 1.827 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 ZNF652 1.135 
miR-200b-3p (and other miRNAs w/seed AAUACUG) -1.790 ZSWIM4 1.474 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 AK4 1.350 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 ANKRD44 1.184 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 ATRN 1.085 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 BTG2 1.410 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 CACNA1I 1.662 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 CCDC24 1.086 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 CGGBP1 1.049 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 CREB1 1.133 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 CTSB 1.121 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 DUSP5 1.262 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 FAM13A 1.877 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 FAM214A 1.164 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 FLNC 2.818 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 GALNT3 1.021 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 JADE1 1.702 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 LAMP2 1.465 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 LOX 2.206 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 LRRFIP1 1.351 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 MEF2D 1.467 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 MTURN 1.126 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 NDRG4 2.087 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 NFE2L1 1.418 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 NUDT10 1.052 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 OTP 1.200 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 PDZD4 1.115 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 POLH 1.072 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 PPME1 1.186 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 RAP1GAP 1.158 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 RNF165 1.396 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 RYBP 1.208 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 SERTAD2 1.719 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 SLC25A36 1.011 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 SNCB 1.427 
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miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 SSPN 1.003 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 TPD52 1.015 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 TRAF5 1.244 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 TRIM9 2.268 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 TUB 1.001 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 UBE2H 1.015 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 WDR1 1.065 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 ZMIZ1 1.221 
miR-218-5p (and other miRNAs w/seed UGUGCUU) -1.231 ZNFX1 1.146 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 ADAM17 1.081 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 AKIRIN1 1.234 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 CAST 1.123 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 FRMD8 2.070 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 HNRNPU 1.486 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 KIAA1244 1.781 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 LCOR 1.124 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 MAFF 1.737 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 PAPSS2 1.109 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 PFKFB3 2.352 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 PPFIA4 1.955 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 SEC14L5 1.227 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 TRIM9 2.268 
miR-224-5p (miRNAs w/seed AAGUCAC) -1.248 ZMAT3 1.827 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 ADM 3.046 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 ANKRD44 1.184 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 AXL 1.805 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 BNIP3L 2.633 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 C8orf58 1.036 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 CABP7 1.076 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 CDKN1C 1.095 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 CITED4 1.154 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 CSRNP2 1.827 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 CYTH2 1.322 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 DENND4B 1.011 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 DNAJB2 1.439 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 FGF11 1.348 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 FGFR3 1.093 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 IRF1 1.183 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 KLHL3 1.151 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 LOX 2.206 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 MAPK7 1.067 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 MXI1 1.003 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 NDRG4 2.087 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 NOTCH1 1.667 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 PDXK 1.523 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 PLOD2 2.106 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 PPM1D 1.536 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 PSTPIP2 1.485 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 PTPRF 1.930 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 RAB11FIP1 1.382 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 RAP2A 1.052 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 RNF165 1.396 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SBK1 1.336 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SEC14L5 1.227 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SERTAD1 1.857 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SESN1 2.178 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SLC41A1 1.067 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 SMAD3 1.013 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 STC2 1.551 
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miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 STX6 1.220 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 TMEM194A 1.019 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 TP53INP1 2.279 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 VPS37D 1.666 
miR-24-3p (and other miRNAs w/seed GGCUCAG) -1.693 ZMAT3 1.827 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 ABCA1 1.079 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 AK4 1.350 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 AKIRIN1 1.234 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 APAF1 1.406 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 ATRN 1.085 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 BEND7 1.136 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 BTG2 1.410 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CALD1 2.292 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CASC10 1.388 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CCDC92 1.133 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CREB1 1.133 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CSRNP1 2.331 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 CSRP2 1.708 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 DUSP5 1.262 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 E2F7 1.181 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 FAM13A 1.877 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 FAM84B 2.062 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 FOXO3 1.169 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 GALNT3 1.021 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 GATA2 1.639 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 GLTP 1.437 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 IER3 2.569 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 LCOR 1.124 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 LEP 1.213 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 LOX 2.206 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 MAGT1 1.458 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 MBTD1 1.374 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 MTURN 1.126 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 MXI1 1.003 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 NOTCH1 1.667 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 NSD1 1.049 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PAPD7 1.062 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PAPSS2 1.109 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PDK1 1.286 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PDXK 1.523 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PLEKHA2 2.391 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 PPME1 1.186 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 RAB11FIP1 1.382 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 RYBP 1.208 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SAV1 1.055 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SBK1 1.336 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SEMA3B 1.395 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SERTAD2 1.719 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SMAD3 1.013 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 STX6 1.220 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 SYDE1 1.791 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 TMSB10/TMSB4X 1.751 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 TRIM13 1.105 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 UNKL 1.007 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 WSB1 1.697 
miR-27a-3p (and other miRNAs w/seed UCACAGU) -2.098 ZMAT3 1.827 
miR-292-3p (and other miRNAs w/seed AGUGCCG) -1.105 GSG1 1.746 
miR-292-3p (and other miRNAs w/seed AGUGCCG) -1.105 SRXN1 1.016 
miR-299a-3p (and other miRNAs w/seed AUGUGGG) -1.159 IKBIP 1.978 
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miR-299a-3p (and other miRNAs w/seed AUGUGGG) -1.159 NSD1 1.049 
miR-299a-3p (and other miRNAs w/seed AUGUGGG) -1.159 TRIM9 2.268 
miR-299a-3p (and other miRNAs w/seed AUGUGGG) -1.159 UBE2H 1.015 
miR-299a-3p (and other miRNAs w/seed AUGUGGG) -1.159 ZNFX1 1.146 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 ABCB6 1.425 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 ARL4A 1.065 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 ATRN 1.085 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 BTG2 1.410 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 CEACAM1 1.622 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 CHIC2 1.236 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 CHSY1 1.071 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 COL7A1 1.255 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 CSRNP2 1.827 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 DNAJB2 1.439 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 DTWD2 1.156 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 E2F7 1.181 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 F11R 1.691 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 FOS 1.838 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 FOXO3 1.169 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 HPCAL4 1.720 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 IL17RD 1.007 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 INA 2.100 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 KDM5B 1.270 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 KLHL28 1.155 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 KREMEN2 1.185 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 LEP 1.213 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 LOX 2.206 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 MAP6D1 1.465 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 MBTD1 1.374 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 MCL1 1.009 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 N4BP2 1.143 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 NSD1 1.049 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 PLEKHA1 1.476 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 PPM1D 1.536 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 PRMT2 1.029 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 PTRF 1.959 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 RAPGEFL1 1.031 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 RIOK3 1.137 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 RNF165 1.396 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 RYBP 1.208 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 SHROOM4 1.366 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 SIDT2 1.420 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 SLC5A8 1.751 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 STAT3 2.118 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 SUN1 1.178 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TP53INP1 2.279 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TPM1 1.385 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TRAF5 1.244 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TRIM9 2.268 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TUBB2A 1.697 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 TUBB2B 1.046 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 UBE2H 1.015 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 UNKL 1.007 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 WDR26 1.935 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 ZBTB5 1.316 
miR-29b-3p (and other miRNAs w/seed AGCACCA) -1.548 ZMIZ1 1.221 
miR-30a-3p (and other miRNAs w/seed UUUCAGU) -1.489 CYR61 1.894 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 AHNAK 2.181 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 ARL4A 1.065 
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miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 ATRN 1.085 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 BNIP3L 2.633 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 C3orf58 1.041 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 CALD1 2.292 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 CAPN5 1.295 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 CEACAM1 1.622 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 CTGF 2.896 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 DDIT4 1.032 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 E2F7 1.181 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 ELAVL3 2.393 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 FAM13A 1.877 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 FAM214A 1.164 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 FAM43A 1.004 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 FOXD1 2.072 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 FOXO3 1.169 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 GALNT3 1.021 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 GPT2 1.076 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 INSIG2 1.733 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 JAG2 1.112 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 JUN 2.508 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 JUNB 1.051 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 KDM3A 2.191 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 KIAA0408 1.050 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 KIAA1244 1.781 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 KIAA1715 1.239 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 KLHL28 1.155 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 LCOR 1.124 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 LOX 2.206 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 MEF2D 1.467 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 MFSD11 1.416 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 N4BP2 1.143 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 NOTCH1 1.667 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 NSD1 1.049 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 P4HA1 1.654 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 P4HA2 2.360 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 PRKAR1A 1.012 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 RALGDS 1.613 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 RASD1 1.248 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 RHOB 2.088 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 RIOK3 1.137 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 RNF165 1.396 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 SBK1 1.336 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 SCN2A 1.391 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 SIDT2 1.420 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 SLC25A36 1.011 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 SLC7A10 1.476 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 STX6 1.220 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 TMEM41B 1.076 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 TNFRSF10B 1.602 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 TNIP1 1.267 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 TP53INP1 2.279 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 TRIM9 2.268 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 UBE2O 1.028 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 UNKL 1.007 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 WDR1 1.065 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 WDR26 1.935 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 YPEL5 1.866 
miR-30c-5p (and other miRNAs w/seed GUAAACA) -2.645 ZNF652 1.135 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 ADAMTS1 1.282 
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miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 AK4 1.350 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 CEBPA 1.103 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 CSRNP1 2.331 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 GCLM 1.134 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 KIAA1244 1.781 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 LRP10 1.022 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 PAM 1.554 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 PDZD4 1.115 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 SCN2A 1.391 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 SERTAD2 1.719 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 SYDE1 1.791 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 TMEM145 1.243 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 UBE2H 1.015 
miR-31-5p (and other miRNAs w/seed GGCAAGA) -1.969 ZNF652 1.135 
miR-362-5p (and other miRNAs w/seed AUCCUUG) -1.410 CHSY1 1.071 
miR-486-5p (and other miRNAs w/seed CCUGUAC) -1.158 CLIP3 1.258 
miR-486-5p (and other miRNAs w/seed CCUGUAC) -1.158 MXI1 1.003 
miR-486-5p (and other miRNAs w/seed CCUGUAC) -1.158 NFE2L1 1.418 
miR-486-5p (and other miRNAs w/seed CCUGUAC) -1.158 RAPGEFL1 1.031 
miR-5107-3p (and other miRNAs w/seed AACCUGU) -1.321 SUN1 1.178 
miR-515-3p (and other miRNAs w/seed AGUGCCU) -1.137 AXL 1.805 
miR-515-3p (and other miRNAs w/seed AGUGCCU) -1.137 FAM13A 1.877 
miR-515-3p (and other miRNAs w/seed AGUGCCU) -1.137 HPCAL4 1.720 
miR-515-3p (and other miRNAs w/seed AGUGCCU) -1.137 PTGR2 1.691 
miR-515-3p (and other miRNAs w/seed AGUGCCU) -1.137 RIMKLA 1.216 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) -1.193 JAG2 1.112 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) -1.193 KIAA1244 1.781 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) -1.193 PCDH7 1.417 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) -1.193 SYAP1 1.464 
miR-516a-3p (and other miRNAs w/seed GCUUCCU) -1.193 TNFRSF10B 1.602 
miR-518a-3p (and other miRNAs w/seed AAAGCGC) -1.330 EGR1 1.452 
miR-518a-3p (and other miRNAs w/seed AAAGCGC) -1.330 TEAD3 1.352 
miR-518a-3p (and other miRNAs w/seed AAAGCGC) -1.330 WDR1 1.065 
miR-520g-3p (and other miRNAs w/seed CAAAGUG) -1.767 TRIM13 1.105 
miR-542-5p (miRNAs w/seed CGGGGAU) -1.775 OSBPL2 1.401 
miR-542-5p (miRNAs w/seed CGGGGAU) -1.775 RGS16 1.133 
miR-551b-3p (and other miRNAs w/seed CGACCCA) -1.222 ANGPTL4 3.123 
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RNA samples from the previously discussed bevacizumab-treated A2780 
tumors showed reduced E-cadherin expression and increased vimentin expression, 
consistent with our in vitro observations (Figure 17a). To elucidate the roles of 
Drosha and Dicer in the EMT process, we silenced Drosha and Dicer in A2780 and 
MCF7 cells, after which we observed significantly decreased E-cadherin and 
increased vimentin expression (Figure 17b, c). There was significant increase in 
migration and invasion of the A2780 cells after silencing of Dicer, Drosha, or both 
(Figure 17d). Correlative analysis of E-cadherin and CA9 in samples from patients 
with ovarian cancer showed a significant inverse correlation between E-cadherin and 
CA9 expression (r = -0.69, p =0.0007). Vimentin expression, however, was positively 
correlated with CA9 expression (r = 0.66, p =0.0013; Figure 17e).  
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Figure 17: (a) mRNA levels of E-cadherin and vimentin in A2780 mouse tumor 
samples treated with bevacizumab. (b) Drosha and Dicer relative mRNA expression 
levels after knockdown using 3 independent siRNA sequences across 3 different 
time points in A2780 cells (c) E-cadherin (top) and vimentin (bottom) expression 
after knockdown of Dicer, Drosha, or both using siRNAs in A2780 cells. (d) Effect of 
Drosha and Dicer on cell migration and invasion in A2780 cells. Drosha and Dicer 
levels were downregulated using siRNAs under normoxic conditions. Rescue of 
Drosha was achieved using siRNAs against ETS1 and ELK1 under hypoxic 
conditions. Dicer expression in cells under normoxia exposure was decreased by 
transfecting cell with miR-630. (e) Pearson correlation between E-cadherin or 
vimentin and hypoxia marker carbonic anhydrase 9 (CA9) expression in clinical 
ovarian tumor samples (n=30). All images shown are representative and data are 
presented as mean ± standard error of the mean of n ≥ 3 experimental groups. *p < 
0.05, **p < 0.01, ***p < 0.001 (Student t test).  
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We created stable cell lines ectopically expressing Dicer and/or Drosha in 
HeyA8 ovarian cancer cells that have low basal Drosha/Dicer expression levels, and 
exposed the cells to hypoxia (Figure 18a, b). There was a significant reduction in 
EMT phenotype, including increased E-cadherin and decreased vimentin expression 
in HeyA8-control cells under hypoxia exposure. We observed disruption of hypoxia 
mediated induction of EMT phenotype upon rescue of Drosha and Dicer in these 
cells (Figure 18c, d). In addition, a reduction in migration and invasion was 
observed in all three cell line variants compared to control cells exposed to hypoxia 
(Figure 18e, f). Next, we ectopically expressed Drosha and Dicer in A2780 cells and 
tested their effects after hypoxia exposure (Figure 18g). There was significant 
reduction in the EMT phenotype in Drosha, Dicer or Drosha + Dicer expressing cells 
compared to control cells exposed to hypoxia (Figure 18g).  
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Figure 18: (a and b) Dicer and Drosha mRNA expression levels in HeyA8 cell line 
variants ectopically expressing Dicer, Drosha, Drosha + Dicer, compared to relative 
levels in A2780 cells. (c) Protein levels of Drosha and Dicer in HeyA8 cells 
ectopically expressing Drosha, Dicer or both, analyzed using immunofluorescence 
microscopy. Scale bar: 200 µm. (d) Expression of E-Cadherin and Vimentin in the 
HeyA8 cells expressing Dicer, Drosha, or both and treated with hypoxia. Data were 
normalized to normoxic cells. (e and f) Migration and invasion assay data showing 
number of cells migrated or invaded in the respective groups of cells ectopically 
expressing Drosha, Dicer, or both and exposed to hypoxia. (g) Expression of Dicer, 
Drosha, and EMT markers in A2780 cells exposed normoxia and hypoxia or in cells 
exposed to hypoxia while ectopically expressing Dicer, Drosha and Drosha + Dicer. 
Data are presented as mean ± standard error of the mean of n ≥ 3 independent 
experimental groups. *p<0.05, **p < 0.01 (Student t test). 
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Next, to understand the biological roles that Drosha and Dicer play in tumor 
progression, we used an orthotopic model of ovarian cancer with luciferase-labeled 
A2780 cells implanted in the ovary. Upon knockdown of Drosha and Dicer using 
siRNAs encapsulated in DOPC nanoliposomes, we observed significant increases in 
aggregate tumor weight (Figure 19) and number and incidence of distant metastatic 
nodules (Figure 19b) in the treatment groups compared with the control group. 
These findings are consistent with the increase in luciferase intensity observed in 
treatment groups (Figure 19c). The tumor metastasis rate was significantly higher 
including rare sites such as liver in the siDicer-DOPC, siDrosha-DOPC, and 
combination treatment groups compared with the control group (Figure 19d), which 
showed metastatic lesions only in the mesentery. Reduction in Dicer or Drosha 
expression in respective treatment groups was also observed (Figure 19e). 
Decreased E-cadherin and increased vimentin protein levels were observed in the 
siDicer, siDrosha, and combination treatment groups compared with the control 
group (Figure 19f). Treatment with siDicer + siDrosha also produced a similar 
pattern as A2780 model in the MCF7 mouse model of breast cancer with significant 
increases in tumor growth and metastatic rate being observed (Figure 20a-d). In the 
HeyA8 in vivo model of ovarian cancer, ectopically expression of Drosha, Dicer, or 
Drosha + Dicer resulted in significant reduction in tumor weight (Figure 20e) and 
number of distant metastatic nodules (Figure 20g). 
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Figure 19: Aggregate tumor weight (a) and number of distant metastatic nodules (b) 
in mice treated with siRNA against Dicer, Drosha, or both compared with the control 
siRNA group (n = 10 per group). (c) Average photon counts from each group of mice 
treated with siRNA against Dicer, Drosha, or both compared to controls. 
Representative bioluminescence images are shown below the respective groups.   
(d) Distant metastatic nodule incidence rate in an orthotopic mouse model of ovarian 
cancer. Metastatic liver nodule representative picture is shown. (e) Drosha and Dicer 
mRNA expression in mouse tumor samples treated with siRNA against Dicer or 
Drosha. (f) Expression of epithelial-to-mesenchymal transition markers (E-cadherin-
Red, vimentin-Red, Nucleus-Blue) in tumor samples from the in vivo experiment 
groups. Scale bar: 200 µm. Aggregate tumor  weight (g) and number of distant 
metastatic nodules (h) in mice implanted with HeyA8 cells ectopically expressing 
Dicer, Drosha and Dicer + Drosha. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t 
test).  
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Figure 20: (a-d) Effect of silencing Dicer and Drosha using siRNAs (seq 2) in the 
MCF7 mouse model of breast cancer. Tumor volume (a) and aggregate tumor 
weight (b) across 2 groups. (c) Representative pictures showing tumor burden (white 
dotted circles) in all the groups. (d) Representative hematoxylin and eosin staining of 
lungs from the in vivo MCF7 mouse model depicting micrometastases in the siDicer 
+ Drosha group (top) and quantification of the micrometastases in the control and 
siDicer + siDrosha groups (bottom; n = 10 per group). Scale bar: 200 µm. (e-f) 
Aggregate tumor weight (e) and number of distant metastatic nodules (f) in mice 
implanted with HeyA8 cells ectopically expressing Dicer, Drosha and Dicer + 
Drosha. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t test).   
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We next sought to determine whether treatment with siETS1/siELK1 could 
reverse the hypoxia-induced downregulation of miRNA biogenesis machinery 
following treatment with bevacizumab. Mice were treated with bevacizumab 2 weeks 
after tumor establishment. There was a significant increase in tumor weight and 
number of metastatic nodules in the bevacizumab treatment group (Figure 21a). In 
mice treated with siETS1/siELK1 and anti-miR-630, we observed significant 
reductions in tumor weight and number of metastatic nodules compared with mice 
treated with bevacizumab alone (Figure 21b, c). A significant increase in CA9 
expression was observed in mice that received anti-VEGF therapy compared with 
control mice (Figure 21d). Importantly, we noted rescue of Drosha expression in the 
siETS/ELK1 treatment group, and rescue of Dicer in anti-miR-630 treatment group 
(Figure 21e). Taken together, these data demonstrate the importance of Drosha in 
tumor progression, as well as the role of ETS1/ELK1 in its regulation.  
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Figure 21: Effect of rescue of Drosha after anti–vascular endothelial growth factor 
(VEGF) therapy in A2780 model. Aggregate tumor weight is shown (a) and number 
of distant metastatic nodules (b) in mice treated with bevacizumab and mice treated 
with siRNAs against ETS+ELK1. Also shown are representative pictures of tumor 
burden (a, bottom) in all treatment groups (n = 5 per group). (c) Distribution of 
metastatic nodules in individual mice groups treated with siDicer, siDrosha and 
siDicer + siDrosha. Hypoxia marker CA9 (d) and Dicer and Drosha (e) mRNA 
expression levels in the tumor samples from the mouse model. All images shown 
are representative and data are presented as mean ± standard error of the mean of 
n ≥ 3 experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t test).  
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Chapter 7: Discussion 
MicroRNAs (miRNAs) are evolutionarily conserved small RNA molecules 
intricately involved in gene regulation [1, 2]. Considering the broad functional 
involvement of miRNAs in cellular homeostasis, it is not surprising that cancer cells 
have altered miRNA levels [2, 84] and that miRNAs are extensively involved in 
cancer progression [85, 86]. Although global miRNA downregulation in cancer has 
been reported [2, 87, 88], the mechanism of this downregulation is not fully 
understood. Drosha and Dicer are key enzymes involved in miRNA biogenesis. We 
and others have previously shown that downregulation of Drosha and Dicer in 
ovarian, lung, and breast cancer is associated with poor patient outcomes [33, 34, 
38, 40, 88]. Although individual regulators of Dicer (e.g., let7) [40, 42, 43, 46, 64] 
have been implicated, the underlying mechanisms are poorly defined. During cancer 
growth, tumors develop significant hypoxia and have been attributed to tumor 
promoting effects and even cancer resistance to therapy [60, 61]. Direct assessment 
of tumor hypoxia in clinical patient samples have showed worst patient out come in 
the cohort with higher hypoxia in the tumors[62].  Cancer cells evolve to grow under 
hypoxia conditions by modifying their key cellular metabolisms and gene alterations 
[60, 61]. Anti-VEGF therapies shown to induce hypoxia and cancers post treatment 
have aggressive tumor recurrence and increased invasiveness but the mechanisms 
are not clear. A previous study showed downregulation of Dicer in hypoxia leading to 
downregulated miRNA in endothelial cells [64]. In addition, EGFR dependent 
Argonaute2 deficiency under hypoxia was shown to lead to downregulated miRNAs 
[46].  However a comprehensive study understanding the impact of hypoxia on 
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cancer cells with regard to miRNA biogenesis has not addressed. My thesis project 
directly addressed this question.  
7.1: Role of hypoxia deregulated miRNAs 
Using breast cancer cell lines cultured under normoxia or hypoxia, a hypoxia 
signature of miRNAs was identified [89]. One of the miRNA in this group is miR-210, 
a transcriptional target of HIF1-α [90]. By use of Ago2 immunoprecipitation and RNA 
sequencing analysis, more than 50 potential gene targets of miR-210 have been 
identified and these targets are involved in hypoxia response, towards better cell 
survival. In orthotopic mouse models of head and neck or pancreatic cancer, loss of 
miR-210 resulted in decreased tumor initiation or growth [90]. The role of miR-210 in 
mitochondrial alteration under hypoxia has been reported. MiR-210 was one among 
the highly upregulated miRNAs in late lung cancer patients samples [91]. In the cell 
line overexpression miR-210, microarray based mRNA signature pathway analysis 
suggested increase in apoptosis. However, target analysis showed miR-210 targets 
SDHD, leading to stabilization of HIF1-α and survival under hypoxia [91]. However, 
another study showed cytoprotective roles of miR-210 by targeting apoptosis-
inducing factor, mitochondrion-associated 3 (AIFM3), known to induce cell death 
[92]. Negative regulation of NF-κB1 in murine macrophages by miR-210 resulting in 
decreased cytokines has been observed, suggesting that miR-210 role is not limited 
to cancer cell signaling [93]. Increased miR-210 in the placenta results in decreased 
IL6/STAT signaling [94].  MiR-210 is also involved in TH17 differentiation. HIF1-α is 
reported as a target of miR-210 in T-cells and, under hypoxia deletion of mir-210 
promoted TH17 differentiation [95]. Considering controversies that exist on role of 
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TH17 differentiation acting as either pro-tumor or anti-tumor, role of miR-210 under 
hypoxia in Th17 differentiation is an important question to be answered.  
MiR-34 is another important miRNA downregulated under hypoxia conditions 
and is involved in influencing cancer cells and tumor microenvironment [96]. Notch1 
and Jagged1 as the target of miR-34a, and also transfection of miR-34a resulted in 
reversal of EMT [96]. In prostate cancer, miR-34 was involved in cancer stem cells 
signaling by direct targeting of CD44 [97]. In colorectal cancer, downregulation in 
miR-34 results in increased IL6 signaling, leading to EMT and cancer metastasis 
[98]. Altogether, these data suggest a mechanism for hypoxia induced increased 
cancer metastasis.  
Another miRNA proven to have important roles in hypoxia response is MiR-
199a. Downregulation of miR-199a under hypoxia exposure results in derepression 
of Hif-1α and Sirtuin 1, resulting in the preconditioning of myocardiocytes [99]. 
Targeting of mTOR and c-met by miR-199a resulted in increased sensitivity to 
doxorubicin [100]. Targeting of PPARδ by miR-199a under cardiac hypoxia resulted 
in metabolic shift toward glycolysis. Treatment with antagomir-199a resulted in mice 
displaying improved cardiac function and restored mitochondrial fatty acid oxidation 
[101]. Eventhough this study is not on cancer mouse model, it stresses on 
importance of miR-199a in modulating hypoxia metabolism. Recently, role of miR-
199 in regulation of HIF signaling in ovarian cancer has been reported [102]. 
Decreased miR-199a expression in the hypoxic condition resulted in increased HIFs 
levels. Exogenous expression of miR-199a decreased HIFs, cell migration, and 
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metastasis of ovarian cancer cells [102], suggesting potential therapeutic strategy to 
target cancer metastasis.  
Eventhough these studies have stressed the importance of hypoxia on 
miRNA alterations, a comprehensive study understanding the impact of hypoxia on 
cancer cells with regard to miRNA biogenesis remains obscure while considering 
significant roles played by the tumor microenvironment on tumor growth. 
7.2: Significance 
Our data shows that tumor hypoxia plays a critical role in the downregulation 
of Drosha and Dicer, leading to downregulated miRNA biogenesis in cancer. Drosha 
is downregulated by ETS1 and ELK1 recruitment of HDAC1 and ARID4B onto the 
promoter, and Dicer is downregulated by miR-630. Using efficient DOPC 
nanoparticles, we delivered siRNAs against ETS1/ELK1 or anti-miR-630 under 
hypoxic conditions in vivo, which in-turn rescued expression of Drosha and Dicer 
and led to significant reductions in tumor growth and metastasis (Figure 22).  
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Figure 22: Overall model of the study showing the mechanistic understanding and 
biological implications of downregulation of Drosha and Dicer under hypoxic 
conditions.  
 
 
  
109 
 
During progression, tumors encounter significant hypoxia owing to abnormal 
vasculature [60]. Emerging studies have shown that hypoxia is involved in promoting 
tumor progression and resistance to therapy [60, 61]. Direct assessment of tumor 
hypoxia in patient samples has demonstrated worse clinical outcomes in patients 
whose tumors had high levels of hypoxia [62]. In addition, emerging data suggest 
that anti-VEGF therapies currently in use in the clinic induce significant hypoxia in 
tumors [103, 104]. We observed that short-term anti-VEGF therapy results in 
potential “angiogenesis rebound,” resulting in increased cancer metastasis. Recent 
report showed hypoxia mediating Ago2 downregulation [46], leading to 
downregulation in group of miRNAs which further strengthens importance of hypoxia 
and miRNA biogenesis link.  
Our laboratory and several others have shown that decreased expression of 
Drosha and Dicer in cancer is associated with poor clinical outcome [33, 34, 38, 40, 
46]. This study sheds light on this clinical observation and provides logical molecular 
understanding of the role of hypoxia in regulating Drosha and Dicer. Use of RNAi-
based gene targeting is an upcoming strategy to develop therapies that target non-
druggable genes using classic chemical agents or antibodies [54, 105, 106]. As 
demonstrated in this study, DOPC liposome-coated siRNA or an anti-miRNA system 
for in vivo delivery acts as a promising therapeutic approach to rescue expression of 
Drosha and Dicer in cancer. In summary, this study provides a clear mechanistic link 
between hypoxia-miRNA biogenesis-tumor progression. These findings could 
translate into the development of new translational approaches that target 
dysregulated miRNA biogenesis. 
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7.3: Future directions 
MiRNAs have a unique advantage in targeted therapy because single 
miRNAs can target multiple genes. As highlighted in earlier reviews, miRNA or 
siRNA delivery to tumors is an attractive, yet challenging approach to improve 
cancer therapy [105, 107-109]. Some of the major challenges are identifying 
clinically feasible delivery approaches for these nucleotides, and designing stable 
synthetic miRNA or siRNA molecules [105, 110]. One of the early miRNA 
therapeutic strategies that showed a significant impact on tumor growth was the 
delivery of miR-34a and Let-7 in lung cancer models [111]. Encouraging results from 
preclinical studies involving miR-34a in several types of cancer have accelerated 
efforts to move miR-34a into clinical trials [112]. Delivery of miR-200 in ovarian, lung, 
breast, and renal cancer preclinical models significantly reduced tumor metastasis 
and angiogenesis and induced vascular normalization by targeting IL-8 and CXCL1 
[54]. We also showed that combining miRNA with siRNA was another viable 
approach for targeting cancer. Combined systemic delivery of miR-520d-3p with 
EphA2 siRNA using the DOPC nanoliposomal system resulted in significant 
reduction in tumor growth and metastasis [113]. We provide evidence in this study, 
use of siRNA/miRNA in combination with anti-VEGF therapy shows promising anti-
tumor effects.  
Apart from therapeutic implications, my study answered several questions which 
advances knowledge of the role of miRNAs in tumor biology and the current role of 
hypoxia in other disease settings. Considering the significant relationship between 
the role of hypoxia in Dicer and Drosha downregulation, we can hypothesize other 
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stress factors such reactive oxygen species in the tumor microenvironment might 
play role in ncRNA modulation as well. To my knowledge, no studies exist to support 
the role of these factors on miRNA biogenesis pathways in cancer.  
With advances in genomic and proteomic approaches, it is of great interest to study 
the role of miRNA-mRNA targets that are deregulated in hypoxia, despite low levels 
of Dicer and Drosha under these conditions. Using a systems-based approach, a 
study of miRNAs upregulated in hypoxia and their mRNA targets will further our 
understanding of hypoxia biology and the molecular mechanisms involved in hypoxia 
promoting tumor progression.  
I further speculate that there are miRNAs that are independent of Dicer and Drosha. 
My study further strengthens this phenomenon and opens up avenues to study 
miRNA biogenesis in this context. Using cell specific knockouts and genomic 
sequencing approaches, we can study miRNAs, which are not influenced by either 
hypoxia or loss of Dicer and Drosha in various disease settings.       
Translational implications: Hypoxia is an integral microenvironment factor aiding 
tumor progression. Ever rising shortage of angiogenesis and improperly developed 
tortuous blood vessels in the tumor lead to the development of hypoxia during tumor 
growth. Interestingly, anti-angiogenesis therapeutic agents targeting VEGF or 
VEGFR are shown to induce hypoxia in tumors, while showing modest therapeutic 
benefits as single agents. There is an increasing need for understanding complex 
biological signaling arising due to hypoxia and cancer cell interactions and for 
developing better therapeutic strategies. MiRNAs are known to regulate key cellular 
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signaling via mRNA modulations. Several miRNAs have previously been reported to 
be altered in the tumor microenvironment; however, clear understandings on 
regulatory mechanisms are not clear. In this study, we elucidate the mechanisms 
governing the downregulation of miRNAs in hypoxic tumors.  We demonstrate that 
hypoxia leads to decreased biogenesis enzymes, Drosha and Dicer. Additionally, 
downstream effector mRNAs were found to be upregulated due to loss of repression 
by miRNAs, which ultimately led to tumor progression. As shown in the study, use of 
siRNAs or anti-miRNAs targeting the deregulatory mechanisms show a great 
promise for rescue of miRNA biogenesis in hypoxic tumors. Overall, we provide 
significant conceptual advancement in understanding the key microenvrionmental 
influences on tumor progression.  
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